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List of Abbreviations
FDDS   - Floating drug delivery system
HCl       - Hydrochloric acid
HPMC   - Hydroxypropylmethylcellulose 
PEO - Polyethylene Oxide
MCC - Microcrystalline cellulose
IPA - Isopropyl alcohol
PVP - Polyvinyl pyrollidone
B.P - British Pharmacopoeia
I.P - Indian Pharmacopoeia
DSC - Differential Scanning Colorimeter
FTIR - Fourier Transform Infrared spectroscopy
U.V - Ultra Violet spectroscopy
HPLC - High Performance Liquid Chromatography
AUC - Area under the curve
AUMC - Area under the first moment curve
Cmax - Peak plasma concentration
tmax - Time of peak concentration
GIT - Gastro intestinal tract
GI - Gastro intestinal
Fig - Figure
q.s  - quantity sufficient
RSD - Relative standard deviation
SD - Standard deviation
RH - Relative Humidity
ICH - International Conference on Harmonization
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Nomenclature
rpm - Revolutions per minute
mm - millimeter
gm - gram
mg - milligram
ml - milliliter
cm - centimeter
mcg/hr - microgram per hour
ng/hr - nanogram per hour
mg/h - milligram per hour
w/w - weight/weight
% - Percentage
hr - Hour
sec - Seconds
mins - Minutes
kg/cm2 - kilogram per square centimeter
gm/ml  - Gram per milliliter
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CHAPTER 1                                                                                          INTRODUCTION
1. INTRODUCTION
1.1. Introduction to Floating Drug Delivery Systems
Oral drug delivery is the most widely utilized route of administration among
all  the  routes  that  have  been  explored  for  systemic  delivery  of  drugs  via
pharmaceutical  products  of  different  dosage  form.  Oral  route  is  considered  most
natural, uncomplicated, convenient and safe due to its ease of administration, patient
acceptance and cost-effective manufacturing process 1.
Pharmaceutical products designed for oral delivery are mainly conventional
drug delivery systems, which are designed for immediate release of drug for rapid
absorption. 
These immediate release dosage forms have some limitations such as 2, 3:
1) Drugs with short half-life require frequent administration, which increase the
chances of missing dose of drug leading to poor patient compliance.
2)  A typical  peak-valley  plasma  concentration-time  profile  is  obtained  which
makes it difficult to attain steady state condition. 
3)  The  unavoidable  fluctuations  in  the  drug  concentration  may lead  to  under
medication or overmedication as the CSS values fall or rise beyond the therapeutic
range. 
4)  The  fluctuating  drug  levels  may  lead  to  precipitation  of  adverse  effects
especially  of  a  drug  with  small  therapeutic  index,  whenever  overmedication
occurs. 
In order to overcome the drawbacks of conventional drug delivery systems,
several  technical  advancements  have  led  to  the  development  of  controlled  drug
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delivery system that could revolutionize method of medication and provide a number
of therapeutic benefits 4. 
1.2. Introduction to Controlled Drug Delivery Systems
Controlled drug delivery systems have been developed which are capable of
controlling the rate of drug delivery,  sustaining the duration of therapeutic activity
and/or targeting the delivery of drug to a tissue 5. 
Controlled drug delivery or modified drug delivery systems are conveniently
divided into four categories.
1) Delayed release 
2) Sustained release 
3) Site-specific targeting
4) Receptor targeting 
More precisely, Controlled delivery can be defined as 6: -
1) Sustained  drug  action  at  a  predetermined  rate  by  maintaining  a  relatively
constant, effective drug level in the body with concomitant minimization of
undesirable side effects.
2) Localized  drug  action  by spatial  placement  of  a  controlled  release  system
adjacent to (or) in the diseased tissue. 
3) Targeted drug action by using carriers or chemical derivatives to deliver drug
to a particular target cell type. 
A controlled  drug  delivery  system  is  usually  designed  to  deliver  the  drug  at
particular rate. Safe and effective blood levels are maintained for a period as long as
the system continues to deliver the drug. 
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1.2.1. Advantages of Controlled Drug Delivery System 
1. Avoid patient compliance problems. 
2. Dosage frequency were reduced 
3. Improve efficiency in treatment 
4. Economy i.e. reduction in health care costs. The average cost of treatment over an
extended  time  period  may  be  less,  with  less  frequency  of  dosing,  enhanced
therapeutic benefits and reduced side effects. The time required for health care
personnel to dispense and administer the drug and monitor patient is also reduced.
1.2.2. Disadvantages of Controlled Drug Delivery System
1) Decreased systemic availability in comparison to conventional dosage forms,
which  may be  due  to  incomplete  release,  increased  first-pass  metabolism,
increased  instability,  insufficient  residence  time  for  complete  release,  site
specific absorption, pH dependent stability etc. 
2) Poor in vitro – in vivo correlation. 
3) Possibility of dose dumping due to food, physiologic or formulation variables
or chewing or grinding of oral formulations by the patient and thus, increased
risk of toxicity. 
4) Retrievals  of  drug  are  difficult  in  case  of  toxicity,  poisoning  or
hypersensitivity reactions. 
5) Reduced potential for dosage adjustment of drugs normally administered in
varying strengths. 
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1.3. Oral Controlled Drug Delivery Systems
Oral controlled release drug delivery is a drug delivery system that provides
the continuous oral delivery of drugs at predictable and reproducible kinetics for a
predetermined period throughout the course of GI transit and also the system that
target the delivery of a drug to a specific region within the GI tract for either local or
systemic action. 
All the pharmaceutical products formulated for systemic delivery via the oral
route of administration, irrespective of the mode of delivery (immediate, sustained or
controlled release) and the design of dosage form (solid dispersion or liquid), must be
developed  within  the  intrinsic  characteristics  of  GI  physiology.  Therefore  the
scientific framework required for the successful development of oral drug delivery
systems consists of basic understanding of (i) Physicochemical, pharmacokinetic and
pharmacodynamic  characteristics  of  the  drug  (ii)  the  anatomic  and  physiologic
characteristics of  the gastrointestinal  tract  and (iii)  physicochemical  characteristics
and the drug delivery mode of the dosage form to be designed. 
The main areas of potential challenge in the development of oral controlled drug
delivery systems are: -
• Development  of  a  drug  delivery  system:  To  develop  a  viable  oral  controlled
release drug delivery system capable  of  delivering a  drug  at  a  therapeutically
effective rate to a desirable site for duration required for optimal treatment. 
• Modulation of gastrointestinal transit time: To modulate the GI transit time so that
the drug delivery system developed can be transported to a target site or to the
vicinity of an absorption site and reside there for a prolonged period of time to
maximize the delivery of a drug dose. 
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• Minimization  of  hepatic  first  pass  elimination:  If  the  drug  to  be  delivered  is
subjected to extensive hepatic first-pass elimination, preventive measures should
be devised to either bypass or minimize the extent of hepatic metabolic effect. 
               Conventional  oral  controlled dosage forms suffer from mainly two
adversities  13.  The  short  gastric  retention  time  (GRT)  and  unpredictable  gastric
emptying  time  (GET).  A relatively  brief  GI  transit  time  of  most  drug  products
impedes the formulation of single daily dosage forms. 
               Altering the gastric emptying can overwhelm these problems. Therefore it is
desirable, to formulate a controlled release dosage form that gives an extended GI
residence  time.  Extended  release  dosage  form  with  prolonged  residence  time  in
stomach are highly desirable for drugs. 
i. That are locally active in stomach, 
ii. That have an absorption window in the stomach or in the upper small intestine, 
iii. That are unstable in the intestinal or colonic environment, 
iv. Have low solubility at high pH values.
1.4. Gastro retentive Dosage Form (GRDF)
It is evident from the recent scientific and patient literature that an increased
interest  in  novel  dosage  forms  that  are  retained  in  stomach  for  a  prolonged  and
predictable period of time exists today in academic and industrial research groups.
One of the most feasible approaches for achieving a prolonged and predictable drug
delivery in  the GI tract  is  to  control  the gastric  residence time (GRT),  i.e.  gastro
retentive dosage form (GRDFs or GRDS). 
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GRDFs extend significantly the period of time over which the drugs may be
released. They not only prolong dosing intervals, but also increase patient compliance
beyond the level of existing controlled release dosage form. 
1.4.1.    Biological Aspects of GRDFs (7, 8, 9, 10, 11)
Role of GI tract: 
Stomach 
The stomach is J-shaped organ located in the upper left hand portion of the
abdomen, just below the diaphragm. It occupies a portion of the epigastric and left
hydrochondriac  region.  The  main  function  of  the  stomach  is  to  store  the  food
temporarily, grind it and then release it slowly into the duodenum. Due to its small
surface area, very little absorption takes place from the stomach. It provides barrier to
the delivery of drugs to small intestine. 
Fig1: Anatomy of Stomach
The stomach is divided into three anatomical regions. i) Fundus ii) Body and
iii) Pylorus (or antrum). The proximal stomach consists of fundus and body, which
serves as a reservoir for ingested materials, whereas the distal region (pylorus) is the
major site of mixing motions, acting as a pump to propel gastric contents for gastric
emptying. Gastric emptying occurs both in fasting as well as fed states.
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The GI tract is always in a state of continuous motility. There are two modes
of motility pattern.  They are digestive mode and inter  digestive mode.  In  case of
fasted state an inter digestive series of electrical events occurs in cyclic manner both
through stomach and small intestine every 2-3 hr. This electrical activity is termed as
inter digestive my electric cycle.
Fig 2: Gastro intestinal motility pattern
PHASE I:  The quiescent period, lasts from 30 to 60 mins and is characterized by a
lack of secretary, electrical and contractile activity.
PHASE II: Exhibits intermittent activity for 20-40 min, during which the contractile
motions increase in frequency and size. Bile enters the duodenum during this phase,
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whereas  gastric  mucus  discharge  occurs  during  the  latter  part  of  phase  II  and
throughout phase III.
PHASE III: Has a housekeeping role and serves to clear all indigestible materials
from  the  stomach  and  small  intestine.  Consequently,  a  controlled-release
gastrointestinal drug delivery system must be capable of resisting the house keeping
action of phase III. Studies revealed that in the fed state, the gastric emptying rate is
slowed since the onset of MMC is delayed. It can be concluded that feeding results in
a lag time before onset of gastric emptying cycle.
PHASE IV: Is the transition period of 0-5 mins between Phase III & I. 
 1.4.2. Requirements for Gastro Retention 
From the discussion of the physiological factors in stomach, to achieve gastro
retention, the dosage form must satisfy some requirements. One of the key issues is
that the dosage form must be able to withstand the forces caused by peristaltic waves
in  the  stomach  and  constant  grinding  and  churning  mechanisms.  It  must  resist
premature  gastric  emptying  and  once  the  purpose  has  been  served,  it  should  be
removed from the stomach with ease  
  1.5. Approaches to Gastric Retention (9, 10, 11, 12) 
Various  approaches  have been pursued to  increase  the retention of  an oral
dosage form in the stomach. These systems include: Floating systems, Bio adhesive
systems, swelling and expanding systems, High density systems, Modified systems
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Fig 3: Classification of gastro retentive drug delivery system
1.5.1. Buoyant/ Floating Systems
Floating  Drug  Delivery  Systems (FDDS)  have  a  bulk  density  lower  than
gastric fluids and thus remain buoyant in the stomach for a prolonged period of time,
without affecting the gastric emptying rate. While the system is floating on the gastric
contents,  the  drug is  released slowly at  a  desired rate  from the system. After  the
release of the drug, the residual system is emptied from the stomach. This results in an
increase  in  the  GRT  and  a  better  control  of  fluctuations  in  the  plasma  drug
concentrations. Floating systems can be classified into two distinct categories, non-
effervescent and effervescent systems.
         
                                       Fig 4: Mechanism of floating system
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Fig 5: Graphic of Buoyant tablet, which is less dense than the stomach fluid and
therefore remains in the fundus.
1.5.2. Bio/Muco-adhesive Systems
Bio/muco-adhesive systems are those which bind to the gastric epithelial cell
surface  or  mucin  and  serve  as  a  potential  means  of  extending  the  GRT of  drug
delivery system in the stomach, by increasing the intimacy and duration of contact of
drug with the biological membrane.
The surface epithelial adhesive properties of mucin have been well recognized
and applied to the development of GRDDS based on bio/muco-adhesive polymers.
The  ability  to  provide  adhesion  of  a  drug  (or  a  delivery system)  to  the  GI wall
provides  a  longer  residence  time in  a  particular  organ  site,  thereby producing an
improved effect in terms of local action or systemic effect. Binding of polymers to the
mucin/epithelial surface can be divided into three broad categories: –
1. Hydration-mediated adhesion.
2. Bonding-mediated adhesion.
3. Receptor-mediated adhesion.
  1.5.3. Swelling and Expanding Systems
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These are the dosage forms, which after swallowing; swell to an extent that
prevents their exit from the pylorus. As a result, the dosage form is retained in the
stomach  for  a  long  period  of  time.  These  systems  may be  named  as  “plug  type
system”, since they exhibit the tendency to remain logged at the pyloric sphincter if
that  exceeds a  diameter  of  approximately 12-18 mm in their  expanded state.  The
formulation is designed for gastric retention and controlled delivery of the drug into
the gastric cavity. Such polymeric matrices remain in the gastric cavity for several
hours even in the fed state. 
1.5.4. High Density Systems
These systems with a density of about 3 g/cm3 are retained in the rugae of
the stomach and are capable of withstanding its peristaltic movements. A density of
2.6-2.8 g/cm3 acts as a threshold value after which such systems can be retained in the
lower part of the stomach. High-density formulations include coated pellets. Coating
is done by heavy inert material such as barium sulphate, zinc oxide, titanium dioxide,
iron powder etc. They are retained in the antrum of stomach as shown in Fig. 6.  
Fig  6:  Graphic  of  heavy tablet,  which  is  denser than  the  stomach fluid  and
therefore sinks to the antrum
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Fig7: Physiology of gastro intestinal tract
 1.5.5. Incorporation of Passage Delaying Food Agents
Food excipients like fatty acids e.g. salts of myristic acid change and modify
the pattern of the stomach to a fed state, thereby decreasing gastric emptying rate and
permitting considerable prolongation of release.  The delay in the gastric emptying
after meals rich in fats is largely caused by saturated fatty acids with chain length of
C10-C14.
1.5.6. Ion Exchange Resins
A coated ion exchange resin bead formulation has been shown to have gastric
retentive properties,  which was loaded with bicarbonates.  Ion exchange resins are
loaded with bicarbonate and a negatively charged drug is  bound to the resin.  The
resultant beads were then encapsulated in a semi-permeable membrane to overcome
the  rapid  loss  of  carbon  dioxide.  Upon  arrival  in  the  acidic  environment  of  the
stomach, an exchange of chloride and bicarbonate ions take place. As a result of this
reaction carbon dioxide was released and trapped in the membrane thereby carrying
beads towards the top of gastric content and producing a floating layer of resin beads
in contrast to the uncoated beads, which will sink quickly.
1.5.7. Osmotic Regulated Systems 13
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It is comprised of an osmotic pressure controlled drug delivery device and an
inflatable  floating  support  in  a  bio  erodible  capsule.  In  the  stomach  the  capsule
quickly disintegrates to release the intra gastric osmotically controlled drug delivery
device. The inflatable support inside forms a deformable hollow polymeric bag that
contains a liquid that  gasifies at body temperature to inflate the bag. The osmotic
controlled  drug  delivery  device  consists  of  two  components  –  drug  reservoir
compartment and osmotically active compartment.
1.6. Types   of   Floating   Drug   Delivery   Systems (FDDS) 14, 15
Based on the mechanism of buoyancy, two distinctly different technologies
have been utilized in development of FDDS which are:
A. Effervescent System, and
B. Non- Effervescent System.
1.6.1    Effervescent System
Effervescent  systems include  use  of  gas  generating agents,  carbonates  (ex.
Sodium bicarbonate) and other organic acid (e.g. citric acid and tartaric acid) present
in the formulation to produce carbon dioxide (CO2) gas, thus reducing the density of
the system and making it float on the gastric fluid. An alternative is the incorporation
of matrix containing portion of liquid,  which produce gas that  evaporates at body
temperature.
These effervescent systems further classified into two types.
I. Gas Generating systems 
II. Volatile Liquid/Vacuum Containing Systems.
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1.6.1.1 Gas – Generating Systems
Intra Gastric Single Layer Floating Tablets or Hydro dynamically Balanced System (HBS)
These are as shown in Fig.8 and formulated by intimately mixing the CO2
generating agents and the drug within the matrix tablet.   These have a bulk density
lower than gastric fluids and therefore remain floating in the stomach unflattering the
gastric emptying rate for a prolonged period. The drug is slowly released at a desired
rate from the floating system and after the complete release the residual system is
expelled from the stomach. This leads to an increase in the GRT and a better control
over fluctuations in plasma drug concentration. 
1. Intra Gastric Single Layer Buoyant Tablet
Fig 8: Intra Gastric Single Layer Buoyant Tablet
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1.6.1.1.1. Intra Gastric Bilayer Floating Tablets
   These are also compressed tablet as shown in Fig 9 and containing two layers i.e. 
i. Immediate release layer and 
ii. Sustained release layer.  
                               Fig 9:  Intra Gastric Bilayer Buoyant Tablet.
1.6.1.1.2. Multiple Unit type floating pills
These  systems  consist  of  sustained  release  pills  as  ‘seeds’ surrounded  by
double layers. The inner layers consist of effervescent agents while the outer layer is
of swellable membrane layer. When the system is immersed in dissolution medium at
body temperature, it sinks at once and then forms swollen pills like balloons, which
float  as  they  have  lower  density.  This  lower  density  is  due  to  generation  and
entrapment of CO2 within the system. 
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Fig 10: A multi-unit oral buoyant dosage system. Stages of floating mechanism:
(A) penetration of water (B) generation of CO2 and floating (C) dissolution of
drug.  Key: (a)  conventional  SR pills  (b)  effervescent layer (c)  swellable  layer
(d) expanded swellable membrane layer (e) surface of water in the beaker (370C)
1.6.1.2. Volatile Liquid / Vacuum Containing Systems 16
1.6.1.2.1.  Intragastric  Floating  Gastrointestinal  Drug  Delivery
System
These  systems  can  be  made  to  float  in  the  stomach  because  of  floatation
chamber, which may be a vacuum or filled with air or a harmless gas, while drug
reservoir is encapsulated inside a micro porous compartment, as shown in Fig11.
Fig11: Intra Gastric Floating Gastrointestinal Drug Delivery Device
 1.6.1.2.2. Inflatable Gastrointestinal Delivery Systems
In these systems, an inflatable chamber is incorporated, which contains liquid
ether that gasifies at body temperature to cause the chamber to inflate in the stomach.
These systems are fabricated by loading the inflatable chamber with a drug reservoir,
DEPARTMENT OF PHARMACEUTICS, A.K.COLLEGE OF PHARMACY
CHAPTER 1                                                                                          INTRODUCTION
which can be a drug, impregnated polymeric matrix, then encapsulated in a gelatin
capsule. 
Fig 12: Inflatable Gastrointestinal Delivery System
After oral administration, the capsule dissolves to release the drug reservoir
together with the inflatable chamber.  The inflatable chamber automatically inflates
and retains the drug reservoir compartment in the stomach. The drug is continuously
released from the reservoir into the gastric fluid. This system is shown in Fig12.
  1.6.1.2.3. Intragastric Osmotically Controlled Drug Delivery System
It is comprised of an osmotic pressure controlled drug delivery device and an 
inflatable floating support in a biodegradable capsule. In the stomach, the capsule quickly 
disintegrates to release the intra gastric osmotically controlled drug delivery device. The 
inflatable support inside forms a deformable hollow polymeric bag that contains a liquid that
gasifies at body temperature to inflate the bag. The osmotic pressure controlled drug 
delivery device consists of two components; drug reservoir compartment and an osmotically 
active compartment. 
The drug reservoir compartment is enclosed by a pressure responsive 
collapsible bag, which is impermeable to vapour and liquid and has a drug delivery orifice. 
The osmotically active compartment contains an osmotically active salt and is enclosed 
within a semi permeable housing. In the stomach, the water in the GI fluid is continuously 
absorbed through the semi permeable membrane into osmotically active compartment to 
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dissolve the osmotically active salt. An osmotic pressure is thus created which acts on the 
collapsible bag and in turn forces the drug reservoir compartment to reduce its volume and 
activate the drug reservoir compartment to reduce its volume and activate the drug release 
of a drug solution formulation through the delivery orifice. 
The floating support is also made to contain a bio erodible plug that erodes
after a predetermined time to deflate the support. The deflated drug delivery system is
then emptied from the stomach. This system is shown in Fig13.
Fig13:  Intragastric Osmotically Controlled Drug Delivery System
1.6.2. Non-Effervescent Systems 16
The Non-effervescent FDDS is based on the mechanism of swelling of polymer or 
bioadhesion to mucosal layer in GI tract. The most commonly used excipients in non-
effervescent FDDS are gel forming or highly swellable cellulose type hydrocolloids, 
polysaccharides and matrix forming material such as Polycarbonate, Polyacrylate, 
Polymethacrylate, polystyrene as well as bioadhesive polymer such as Chitosan and 
Carbopol. The various types of this system are as:
1.6.2.1. Single Layer Floating Tablets
They  are  formulated  by  intimate  mixing  of  drug  with  a  gel-forming
hydrocolloid, which swells in contact with gastric fluid and maintain bulk density of
less than unity. The air trapped by the swollen polymer confers buoyancy to these
dosage forms. 
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1.6.2.2. Bilayer Floating Tablets 
A bilayer tablet contains two layers, one immediate release layer which release
initial  dose  from system while  the  another  sustained  release  layer  which  absorbs
gastric fluid, forming an impermeable colloidal gel barrier on its surface, and maintain
a bulk density of less than unity and thereby it remains buoyant in the stomach.   
1.6.2.3. Alginate Beads
Multi unit floating dosage forms were developed from freeze-dried calcium
alginate.  Spherical  beads  of  approximately 2.5  mm diameter  can  be  prepared  by
dropping  a  sodium  alginate  solution  into  aqueous  solution  of  calcium  chloride,
causing  precipitation  of  calcium  alginate  leading  to  formation  of  porous  system,
which can maintain a floating force for over 12 hours. 
1.6.2.4. Hollow Microspheres
Hollow  microspheres  (micro  balloons),  loaded  with  drug  in  their  outer
polymer  shells  were  prepared by a  novel  emulsion-solvent  diffusion method.  The
ethanol:  dichloromethane solution of the drug and an enteric  acrylic  polymer was
poured into an agitated aqueous solution of  PVA that  was thermally controlled at
400C. 
The  gas  phase  generated  in  dispersed  polymer  droplet  by  evaporation  of
dichloromethane formed an internal cavity in microsphere of polymer with drug. The
micro  balloons  floated  continuously  over  the  surface  of  acidic  dissolution  media
containing surfactant for more than 12 hours in vitro.
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Fig14: Hallow microspheres
1.7. Factors Controlling Gastric Retention Time of Dosage Form 
The gastric  retention time (GRT) of dosage form is controlled by several
factors that affect their efficacy as a gastro retentive system. 
• Density of dosage form: –density of gastric fluid is reported to be 1.004g/cm3,
density of the dosage form should be less than this for buoyancy, so that it  is
retained in stomach for longer period of time. The dosage form may be having a
high density in the beginning, but due to reduction in density by swelling it will
float in stomach.
• Size of the dosage from: –studies on the effect of particle size on gastric retention
have been inconclusive. In general it is known that indigestive solids larger than
1-2mm are retained in stomach throughout the post-prandial period, after which
they are emptied in stomach throughout the post-prandial period, after which they
are emptied by cyclically recurring burst of inter digestive gastric contractions.
However  studies  have  suggested  that  this  observation  cannot  be  generalized.
Many recent studies have shown that non-disintegrating tablets as large as 7mm
can be emptied from human stomach during the post-prandial period, while 13mm
tablets are retained until arrival of subsequent sweeping “housekeeper wave”. This
emphasizes the need for size enlargement of DF in stomach in order to prolong
GRT.
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• Shape of  dosage form – Tetrahedron and ring-shaped devices with a  flexural
modulus of 48 and 22.5 kilo pounds per square inch (KPSI) are reported to have
better GRT. 90% to 100% retention at 24 hours compared with other shapes.
• Single or multiple unit formulation – Multiple unit formulations show a more
predictable  release  profile  and  insignificant  impairing  of  performance  due  to
failure of units, allow co-administration of units with different release profiles or
containing incompatible substances and permit a larger margin of safety against
dosage form failure compared with single unit dosage forms.
• Fed or unfed state – Under fasting conditions, the GI motility is characterized by
periods of strong motor activity or the migrating myoelectric complex (MMC)
that occurs every 1.5 to 2 hours. The MMC sweeps undigested material from the
stomach and, if the timing of administration of the formulation coincides with that
of the MMC, the GRT of the unit can be expected to be very short. However, in
the fed state, MMC is delayed and GRT is considerably longer.
• Nature of meal – Feeding of indigestible polymers or fatty acid salts can change
the  motility  pattern  of  the  stomach to  a  fed  state,  thus  decreasing the  gastric
emptying rate and prolonging the drug release.
• Caloric content – GRT can be increased by four to 10 hours with a meal that is
high in proteins and fats.
• Frequency of feed – The GRT can increase by over 400 minutes when successive
meals are given compared with a single meal due to the low frequency of MMC.
• Gender – Mean ambulatory GRT in males (3.40.6 hours) is less compared with
their age and race-matched female counterparts (4.6±1.2 hours), regardless of the
weight, height and body surface.
• Age – Elderly people, especially those over 70, have a significantly longer GRT.
1.8 Advantages of FDDS 17, 18 
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Floating dosage systems form important technological drug delivery systems
with gastric retentive behavior and offer several advantages in drug delivery. These
advantages include: 
1. Improved drug absorption, because of increased GRT and more time spent by the
dosage form at its absorption site. 
2. Controlled delivery of drugs.
3. Delivery of drugs for local action in the stomach. 
4. Minimizing  the  mucosal  irritation  due  to  drugs,  by  drug  releasing  slowly  at
controlled rate. 
5. Treatment of gastrointestinal disorders such as gastro-esophageal reflux. 
6. Simple and conventional equipment for manufacture. 
7. Ease of administration and better patient compliance. 
8. Site-specific drug delivery.
1.9 Disadvantages of FDDS 
1. Gastric retention is influenced by many factors such as gastric motility, pH and
presence of food. These factors are never constant and hence the buoyancy cannot
be predicted.
2. Drugs that  cause irritation and lesion to gastric  mucosa are not  suitable  to  be
formulated as floating drug delivery systems.
3. High variability in gastric emptying time due to its all or non-emptying process.
4. Gastric emptying of floating forms in supine subjects may occur at random and
becomes highly dependent on the diametral size. Therefore patients should not be
dosed with floating forms just before going to bed. 
Table1: 1. 14 Lists of Drugs - Floatable Drug Delivery Systems
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S. No.
DOSAGE
FORM
DRUGS
1 Microspheres Aspirin, Grisiofulvin, p-nitroanilline, Ibuprofen, Terfinadine, 
Tranilast.
2 Granules Diclofenac sodium, Indomethacin, Prednisolone
3 Films Cinnarizine
4 Powders Several basic drugs
5 Capsules Chlordiazepoxide HCl, Diazepam, Furosemide, L-Dopa, 
benserazide, Misoprostol, Propranolol HCl, Ursodeoxycholic
acid
6 Tablets/pills Acetaminophen, Acetylsalicylic acid, Amoxicillin trihydrate, 
Ampicillin, Atenolol, Cinnazirine, Diltiazem, Fluorouracil, 
Isosorbide mononitrate, Isosorbide dinitrate, Piretanide, 
Prednisolone, Quinidine gluconate, Riboflavin-5-phosphate, 
Sotalol, Theophylline, Verapamil HCl
Table 2: 1.15 Marketed Products of FDDS
SR.
NO
.
BRAND
NAME
DRUG (DOSE)
COMPANY,
COUNTRY
REMARKS
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1. Modular® Levodopa (100 
mg), Benserazide 
(25 mg)
RocheProducts, 
USA
FloatingCR 
capsule
2. Val release® Diazepam (15 mg) Hoffmann-
Larches, USA
Floating capsule
3. Liquid 
Gavison®
Al hydroxide (95 
mg), Mg carbonate
(358 mg)
GlaxoSmith 
Kline, India
Effervescent 
floating liquid 
alginate 
preparation
4. Topalkan® Al-Mg antacid Pierre Fabre 
Drug, France
Floating liquid 
alginate 
preparation
5. Conviron Ferrous sulphate Ranbaxy, India Colloidalgel 
forming FDDS
6. Cifran OD® Ciprofloxacin(1 
gm)
Ranbaxy, India Gas-generating 
floating tablet
7. Cytotec® Misoprostal (100 
mcg/200 mcg)
Pharmacia, USA Bilayer floating 
capsule
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Miteshkumar J.Patel  et  al19.,  The aim of this study was to develop a new intra-
gastric floating in situ gelling system for controlled delivery of levetiracetam for the
treatment of partial onset seizures. High dose of levetiracetam (750 to 1000 mg) is
difficult to incorporate in floating tablets but can easily be given in liquid dosage form
released. Sodium alginate-based in-situ gelling systems were prepared by dissolving
various  concentrations  of  sodium alginate  in  deionized  water,  to  which  drug  and
calcium carbonate were added. Fourier transform infrared spectroscopy (FTIR) was
used to check the presence of any interaction between the drug and the excipients. A
32  full  factorial  design  was  used  for  optimization.  The  concentrations  of  sodium
alginate (X1) and calcium carbonate (X2) were selected as the independent variables.
The amount of the drug released after 1 h (Q1) and 6 h (Q6) and 12 h (Q12) and the
viscosity  of  the solution were  selected  as  the dependent  variables.  The gels  were
studied for their viscosity, in-vitro buoyancy and drug release. Other ingredient like
HPMC  K100M  used  for  strength  forming  polymer,  sodium  citrate  is  used  for
liquefying solution. 
 Siahi  et  al20.,  designed  and  evaluated  1-  and  3-  layer  matrices  of  verapamil
hydrochloride  for  sustaining  its  release,  the  kinetic  analysis  of  drug  release  from
matrices  exhibiting  sustained  release  indicated  that  release  was  predominantly
attributable to the contribution made by Fickian diffusion.
 Krojel et al21., developed and evaluated floating and pulsatile drug delivery systems
based on a reservoir system consisting of a drug-containing effervescent core and a
polymeric  coating.  For  the  floating  system,  a  polymer  coating  with  a  high
elongationvalue and high water- and low CO2 permeabilities was selected (Eudragit®
RL/acetyltributyl citrate 20%, w/w) in order to initiate the effervescent reaction and
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the floating process rapidly, while for the pulsatile DDS, a weak, semipermeable film, which
ruptured after a certain lag time was best (ethyl cellulose/dibutyl sebacate 20%, w/w). 
 S. Sungthongjeeh et al22., developed a multiple-unit floating drug delivery system based on
gas formation technique was developed in order to prolong the gastric residence time and to
increase the overall  bioavailability  of  the dosage form.  The system consists  of  the drug-
containing core pellets prepared by extrusion–spheronization processes.  The time to float
decreased as amount of the effervescent agent increased and coating level of gas-entrapped
polymeric membrane decreased. The optimum system could float completely within 3 min
and maintained the buoyancy over a period of 24 h. 
 Brijesh  s  dev  et  al23., prepared  a  gastroretentive  drug  delivery  system  of  ranitidine
hydrochloride. The effects of citric acid and stearic acid on drug release profile and floating
properties  were  investigated.  The results  of  the full  factorial  design  indicated  that  a  low
amount of citric acid and a high amount of stearic acid favors sustained release of ranitidine
hydrochloride from a gastroretentive formulation. 
 Sunil  k jain et  al24., developed and evaluated of carrier  based orlistat  microspheres  for
gastric delivery consisting of eutragit s as polymer, by solvent evaporation method and to
evaluate  their  gastro  retentive  and  controlled  release  profile.  The  effect  of  various
formulation and process variables on the particle morphology.
 Patel  D M et  al25.,   developed  gastroretentive  drug  delivery system of  carbamazepine
formulation using simplex lattice design.  This approach used to achieve increased gastric
residence time for the dosage form and sustain drug release.
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Gambhir M N et al26., developed and invitro evaluation of an oral floating matrix
tablets formulation of diltiazem hydrochloride to prolong gastrointestinal  residence
time and increase it bioavailability. The tablets were prepared by direct compression
method, using polymers such as hydroxyl methyl propyl cellulose compritol. Alone or
in combination. Sodium carbonate was incorporated a gas generating agent.
 Baumgartner  et  al27., developed  a  optimization  of  floating  matrix  tablets  and
evaluation of their gastric residence time. In vivo experiments with fasted state beagle
dogs revealed prolonged gastric residence time. On radiographic images made after
30 minutes of administration, the tablet was observed in animal’s stomach and the
next image taken at 1 hour showed that the tablet had altered its position and turned
around.
 R  D  kale  et  al28., developed  a  multiple  unit  floating  drug  delivery  system  of
piroxicam was prepared using enteric polymer and emulsification solvent evaporation
method. The microspheres remained buoyant continuously over surface of the acidic
media containing surfactant for a period of 8-12 h in vivo.
 Fraces et al29.,   designed a floating dosage forms to proling a gastro retention of the
calcium alginate beads. It is a type of multi unit floating gel beads synthesized with
calcium alginate, sunflower oil, by gelation process. The alginate beads were able to
continuously float over the medium for 24 h. under constant agitation.
 Shradda s  badve et  al30., developed  hollow/porous  calcium pectinate  beads  for
floating  pulsatile  drug  delivery  of  diclofenac  sodium  intended  for
chronopharmacology by process of acid base reaction during ionotropic crosslinking
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 Mahesh chavanpati et al31.,  studied developed of sustained release gastroretentive
drug delivery system of oflaxacin in-vivo and in-vitro evaluation by using polymers as
psyllium husk, hydroxyl propyl methyl cellulose K100M.
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Aim
To prepare and evaluate Levetiracetam floating tablets based on gas forming
agent.
Objectives of the study
Levetiracetam is a broad-spectrum antiepileptic drug used in the treatment of
partial-onset  seizures,  myoclonic  seizures,  and  generalized  tonic-clonic  seizures.
Levetiracetam though rapidly and completely absorbed in the stomach and the small
intestine,  is  comparatively  less  bioavailable  in  the  lower  part  of  the  intestine.
Levetiracetam is used as a monotherapy for seizures. Levetiracetam may be used as
an alternative for  the syndrome of juvenile absence epilepsy.Treatment of patients
with seizures or epilepsy is often challenging. A person suffering from seizures has to
strictly adhere to the medications every day. Even missing a dose of the drug may
lead to fatality of the patients. The nootropic drug levetiracetam, has a half life of 6-8
hrs,  suffers  the  disadvantage  of  multiple  dosing  in  a  day.  To  eradicate  the
disadvantage,  the study was designed  to reduce  the dosage  by designing it  into  a
floatable drug delivery which will serve both the purpose of enhancing the absorption
in the upper part of the GIT and further sustaining the release of the drug.  
PLAN OF WORK
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In the present research work, formulation of levetiracetam floating tablets for
oral  controlled drug delivery system was done with various  polymers  like HPMC
K4M, HPMC E15 and CARBOPOL974 p.
1. Formulation  of  Levetiracetam  floating  tablets  by  wet  granulation  method,
using as hydrophilic polymers HPMC K4M,HPMC E15 and carbopol 974 p
and sodium bicarbonate as the gas-generating agent.
2. Twelve  formulations  were  formulated  with  different  proportions  of  HPMC
K4M and HPMC E15M and CARBOPOL 974 P. 
The  prepared  floating  tablets  will  be  evaluated  for  parameter  related  to
controlled drug delivery system like evaluation of granules and evaluation of tablets.
A. Evaluation of Granules:
I)  Angle of Repose
II) Bulk density and tapped density
III) Compressibility index
 IV) Hausner ratio
B. Evaluation of Tablets             
I) Hardness
II) Friability
III) Uniformity of weight
IV) Drug content estimation
V) Buoyancy determination;         
a) Buoyancy lag time
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b) Duration of Buoyancy
VI) Swelling Index 
1. To carry out the in-vitro release studies of levetiracetam from the formulation
by using dissolution apparatus.
2. To carry out pre-formulation studies  and compatibility studies  for  possible
drug and polymer interactions by using FTIR technique.      
3. This  prepared floating tablets   may fulfill the need of present work.
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CHAPTER IV                                                                                                                                    DRUG PROFILE   
LEVETIRACETAM
Structure
 
                                         
                                          
Molecular formula
:  C8H14N2O2
Molecular weight :  170.21
Chemical name : (S)-ethyl-2-oxo-1-pyrolidineacetamide (2S)-
(2-oxopyrolidin-1-yl) butanamide   
IUPAC Name : (S)-2-(2-oxopyrrolidin-1-yl)butanamide
Therapeutic category :  Anticonvulsant.
Description : White or almost white powder. 
Solubility                               :             Very soluble in water soluble in acetonitrile. 
Practically  Insoluble in hexane                            
Dose : 250-1000 mg 
Plasma half-life               :    6-8 hours
Elimination half life        : 5-7 hours for every 8 to 12 hours
Absolute bioavailability : Approx.100% 
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PHARMACOLOGY: 
Mechanism of action: 
The  precise  mechanism(s)  by  which  levetiracetam  exerts  its  antiepileptic
effect  is  unknown.  The  antiepileptic  activity  of  levetiracetam  was  assessed  in  a
number of animal models of epileptic seizures. Levetiracetam did not inhibit single
seizures  induced  by  maximal  stimulation  with  electrical  current  or  different
chemoconvulsants and showed only minimal activity in submaximal stimulation and
in threshold tests. Protection was observed, however, against secondarily generalized
activity  from focal seizures  induced  by  pilocarpine  and  kainic  acid,  two
chemoconvulsants that induce seizures that mimic some features of human complex
partial  seizures  with  secondary  generalization.  Levetiracetam  also  displayed
inhibitory properties in the kindling model in rats, another model of human complex
partial seizures, both during kindling development and in the fully kindled state. The
predictive  value  of  these  animal  models  for  specific  types  of  human epilepsy is
uncertain.
In vitro and in vivo recordings of epileptiform activity from the hippocampus
have shown that levetiracetam inhibits burst firing without affecting normal neuronal
excitability,  suggesting  that  levetiracetam  may  selectively  prevent  hyper
synchronization of epileptiform burst firing and propagation of seizure activity.
Levetiracetam at concentrations of up to 10 µM did not demonstrate binding
affinity for  a  variety  of  known  receptors,  such  as  those  associated  with
benzodiazepines, GABA (gamma-aminobutyric acid), glycine, NMDA (N-methyl-D-
aspartate), re-uptake sites,  and  second  messenger  systems.  Furthermore, in
vitro studies have failed to find an effect of levetiracetam on neuronal voltage-gated
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sodium or  T-type  calcium currents  and  levetiracetam  does  not  appear  to  directly
facilitate GABAergic neurotransmission. However, in vitro studies have demonstrated
that levetiracetam opposes the activity of negative modulators of GABA- and glycine-
gated currents and partially inhibits N-type calcium currents in neuronal cells.
A saturable  and stereoselective  neuronal  binding site  in rat brain tissue  has
been described for levetiracetam. Experimental data indicate that this binding site is
the synaptic vesicle protein SV2A, thought to be involved in the regulation of vesicle
exocytosis. Although the molecular significance of levetiracetam binding to SV2A is
not understood, levetiracetam and related analogs showed a rank order of affinity for
SV2A which correlated with the potency of their antiseizure activity in audiogenic
seizure-prone mice. These findings suggest that the interaction of levetiracetam with
the SV2A protein may contribute to the antiepileptic mechanism of action of the drug.
Pharmacodynamics
Effects on QTc Interval
The effect of KEPPRA on QTc prolongation was evaluated in a randomized,
double-blind,  positive-controlled  (moxifloxacin  400  mg)  and  placebo-controlled
crossover study of KEPPRA (1000 mg or 5000 mg) in 52 healthy subjects. The upper
bound  of  the  90%  confidence  interval  for  the  largest  placebo-adjusted,  baseline-
corrected  QTc  was  below  10  milliseconds.  Therefore,  there  was  no  evidence  of
significant QTc prolongation in this study.
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Pharmacokinetics
Absorption and Distribution
Absorption  of  levetiracetam  is  rapid,  with  peak plasma concentrations
occurring in about an hour following oral administration in fasted subjects. The oral
bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are
bioequivalent  in  rate  and extent of  absorption.  Food does  not  affect  the  extent  of
absorption of levetiracetam but it decreases Cmax by 20% and delays Tmax by 1.5
hours. The pharmacokinetics of levetiracetam are linear over the dose range of 500-
5000  mg.  Steady  state  is  achieved  after  2  days  of  multiple  twice-daily  dosing.
Levetiracetam and its major metabolite are less than 10% bound to plasma proteins;
clinically  significant  interactions  with other  drugs  through competition for  protein
binding sites are therefore unlikely.
Metabolism
Levetiracetam is not extensively metabolized in humans. The major metabolic
pathway is  the enzymatic  hydrolysis  of  the  acetamide  group,  which  produces  the
carboxylic  acid  metabolite,  ucb  L057  (24%  of  dose)  and  is  not  dependent  on
any liver cytochrome P450 isoenzymes. The major metabolite is inactive in animal
seizure  models.  Two  minor  metabolites  were  identified  as  the  product  of
hydroxylation of the 2-oxo-pyrrolidine ring (2% of dose) and opening of the 2-oxo-
pyrrolidine ring in position 5 (1% of dose). There is no enantiomeric interconversion
of levetiracetam or its major metabolite.
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Elimination
Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by
either dose or repeated administration. Levetiracetam is eliminated from the systemic
circulation  by  renal excretion  as  unchanged  drug  which  represents  66%  of
administered  dose.  The  total  body  clearance  is  0.96  mL/min/kg  and  the  renal
clearance is 0.6 mL/min/kg. The mechanism of excretion is glomerular filtration with
subsequent  partial  tubularreabsorption.  The  metabolite  ucb  L057  is  excreted  by
glomerular  filtration  and  active  tubular  secretion  with  a  renal  clearance  of  4
mL/min/kg.  Levetiracetam  elimination  is  correlated  to creatinine clearance.
Levetiracetam clearance is reduced in patients with impaired renal function [see Use
In Specific Populations and DOSAGE AND ADMINISTRATION].
PREPARATIONS: Tablets (immediate release): 250, 500, 750 and 1000 mg. Tablets
(extended release): 500and 750 mg. Oral solution: 100 mg/ml. Injection solution: 100
mg/ml.
STORAGE: Levetiracetam should be stored at 25 C (77 F). Brief storage at 15-30 C
(59-86 F) is acceptable.
PRESCRIBED FOR: Levetiracetam is used in combination with other antiseizure
medications to treat myoclonic, partial onset, or tonic clonic seizures in children and
adults.
DOSING: The  recommended  daily  dose  of  levetiracetam  in  adults  is  3000  mg.
Therapy is initiated with 1000 mg daily (500 mg twice daily) and increased by 1000
mg/day every two weeks up to the maximum recommended dose of 3000 mg/day.
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Immediate release tablets, oral solution, and intravenous solutions are administered
twice  daily,  and  extended  release  tablets  are  administered  once  daily.  The
recommended daily dose for children is 60 mg/kg (30 mg/kg twice daily). Therapy is
initiated with 20 mg/kg (10 mg/kg twice daily) and increased by 20 mg/kg every two
weeks until the recommended daily dose of 60 mg/kg is reached.
DRUG  INTERACTIONS: Probenecid (Benemid)  reduces  the  elimination  of
levetiracetam by the kidneys, potentially doubling the concentration of levetiracetam
in the body. This could lead to side effects from probenecid.
PREGNANCY: Levetiracetam has not been adequately studied in pregnant women. 
Levetiracetam is used during pregnancy only if the benefit justifies the potential risk 
to the fetus.
NURSING MOTHERS: Levetiracetam is excreted in breast milk. To avoid potential
serious  side  effects  in  infants  who  are breastfeeding mothers  should  consider  not
breast-feeding while taking levetiracetam.
SIDE  EFFECTS: Common  side  effects  associated  with  levetiracetam
includeheadache, sleepiness, weakness, dizziness, and infection. Difficulty walking or
moving, hostility, irritability, mood swings, anxiety, hallucinations, and delusions also
have been associated with levetiracetam. A small number of patients may experience
a  decrease  in  red  or  white  blood  cell  counts.  Like  other  antiseizure  medications,
levetiracetam should not be discontinued suddenly because of the risk of increased
seizure activity.
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Antiepileptic medications have been associated with increased risk of suicidal
thinking  and  behavior.  Anyone  considering  the  use  of  antiepileptic  drugs  must
balance this risk of suicide with the clinical need. Patients who are started on therapy
should  be  closely  observed  for  clinical  worsening,  suicidal  thoughts,  or  unusual
changes in behavior.
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CHAPTER IV                                                                                                                                    DRUG PROFILE   
Elimination
Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by
either dose or repeated administration. Levetiracetam is eliminated from the systemic
circulation  by  renal excretion  as  unchanged  drug  which  represents  66%  of
administered  dose.  The  total  body  clearance  is  0.96  mL/min/kg  and  the  renal
clearance is 0.6 mL/min/kg. The mechanism of excretion is glomerular filtration with
subsequent  partial  tubularreabsorption.  The  metabolite  ucb  L057  is  excreted  by
glomerular  filtration  and  active  tubular  secretion  with  a  renal  clearance  of  4
mL/min/kg.  Levetiracetam  elimination  is  correlated  to creatinine clearance.
Levetiracetam clearance is reduced in patients with impaired renal function [see Use
In Specific Populations and DOSAGE AND ADMINISTRATION].
PREPARATIONS: Tablets (immediate release): 250, 500, 750 and 1000 mg. Tablets
(extended release): 500and 750 mg. Oral solution: 100 mg/ml. Injection solution: 100
mg/ml.
STORAGE: Levetiracetam should be stored at 25 C (77 F). Brief storage at 15-30 C
(59-86 F) is acceptable.
PRESCRIBED FOR: Levetiracetam is used in combination with other antiseizure
medications to treat myoclonic, partial onset, or tonic clonic seizures in children and
adults.
DOSING: The recommended daily dose of levetiracetam in adults is 3000 mg. 
Therapy is initiated with 1000 mg daily (500 mg twice daily) and increased by 1000 
mg/day every two weeks up to the maximum recommended dose of 3000 mg/day.
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HYDROXY PROPYL METHYL CELLULOSE 
General Descriptions32
Nonproprietry Names: BP: Hypromellose
USP : Hypromellose
Synonyms : Methocel, HPMC2208, Benecal MHPC, 
Pharmacoat.
Description : It is odorless & tasteless, white or creamy white
 colored Fibrous or granular powder.
Structural Formula
Functional categories32 : Tablet binder, Coating agent, Film former
Stabilizing  agent,  Suspending  agent,  Viscosity
increasing agent.
Solubility : It is soluble in cold water but insoluble in
Chloroform, ethanol (95%) & ether but  Soluble in 
 mixture of ethanol & dichloromethane mixture of 
methanol & dichloromethane, mixture of alcohol.
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Viscosity (dynamic):
A  wide  range  of  viscosity  types  are  commercially  available.  Aqueous
solutions are most commonly prepared, although hypromellose may also be dissolved
in aqueous alcohols suchas ethanol and propan-2-ol provided the alcohol content is
less  than  50%  w/w.Dichloromethane  and  ethanol  mixtures  may  also  be  used  to
prepare viscous Hypromellose
pH : 5.5 – 8.0 for a 1 % w/w aqueous 
solution.
Melting point : Brown at 190- 2000C; chars at 225-2300C.
Specific gravity : 1.26
Loss on drying : < 5.0 %
Density (bulk) : 0.341 gm / cm3 
Density (tapped ) : 0.557 gm / cm3 
Stability and storage Conditions33: Hypromellose powder is a stable 
material although it is hydroscopic after 
drying. Solutions are stable at pH 3. 
Upon heating and cooling hypromellose 
undergoes a reversible gel 
transformation. Viscosity of solutions is 
reduced by increasing the temperature. 
Depending upon the grade and 
concentration of material, the gel point is
50-90°C. It is stable material although it 
is hygroscopic after drying. It should be 
stored in a well -closed container in a 
cool dry place.
Incompatibilities :  Incompatible with some oxidizing   Agents.
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Applications34, 35 : It is widely used oral & topical pharmaceutical 
formulations  primarily  used  in  film-coating,  
binder in tablets in concentrations of 2 – 5 %.
CARBOPOL
Structure:
Carbopol-974,  a  synthetic  high  molecular  weight,  non-linear  polymer  of
acrylic acid cross-linked with polyalkenyl polyether with average molecular weight
3×106 Daltons. It contains not less than 56% and not more than 68% of carboxylic
acid (-COOH) groups.
Synonym : Acritamer, Acrylic acid polymer carboxyl vinyl polymer
Non proprietary names:
BP : carbomer, 
USP : carbomer
Chemical name : carboxyl polymethylene
Empirical formula : (C3HO) (-C H -Sucrose)
Category : Bioadhesive, Emulsifying, suspending & viscosity 
enhancing  agent,  tablet  binder  and  release-modifying
agent.
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Description :  white, fluffy, acidic, hygroscopic powder with a
slight characteristic odour
Solubility : After neutralization with alkali hydroxides or 
amines, soluble in water, in ethanol (96%) and 
in glycerol.
PH :  2.5-3.0 (1% aqueous solution)
Glass transition temperature: 100-105°C
Melting point : Decomposition occurs within 30 min at 260°C
Specific gravity : 1.41
Viscosity : Carbomers disappears in water to form acidic 
colloidal solutions of low viscosity which when
neutralized produce highly viscous gels. 29, 400
to 39,400 cps at 25°C (0.5% neutralized aqueous
solution)
Stability and storage : Carbomers are stable, though hygroscopic 
materials and can be heated at temperatures 
below 104°C for up to 2 hours without affecting 
their thickening efficiency.
Applications : It is used as thickening, emulsifying and gelling 
agent. It is used as a tablet binder and matrix \
forming agent in sustained – release 
formulations affording zero- to near – zero – 
order release. It is used as the bioadhesive 
component in mucoadhesive ointments, gels and
tablets.
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Safety : carbomers are regarded as nontoxic and non 
irritant.
 POLYVINYL PYRROLIDINE
1. General discriptions36.
i.Nonproprietary names 
BP : Povidone
USP :  Povidone 
USP :  Polyvidonum 
ii. Synonym
Plasdone; PVP; Poly [1-(2-oxo-1-pyrrolidinyl)ethylene]; Polyvidone; 1-vinyl-
2-Pyrrolidine polymer.
iii. Chemical Name 
1-Ethenyl-2-pyrrolidinone homopolymer;
 
iv.  Emprical Formula
(C6H9NO)
v.  Molecular Weight
250-3000000
 vi.  Functional category
Disintegrant; dissolution aid; suspending agent and tablet binder.    
2. Applications in Pharmaceutical Formulation or Technology             
Polyvinyl pyrrolidine(PVP) is used in a variety of pharmaceutical 
                - formulations it is Primarily used in solid dosage forms
- In tabletting PVP solutions are used in wet granulation as binders.
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               - PVP is also added in dry form to the powder blend and granulated in situ
by the addition of water, alcohol or viscosity increasing agents in a number of topical
and oral suspensions and solutions.
Table no:3
USE
CONCENTRATIONS
(%)
Carrier for drugs
Dispersing agent
Eye drops
Suspending  agent
Tablet binder; tablet
Diluents or coating agent
10-25
Up to 5
2-10
Up to 5
0.5-5
 
3. Description37    
         Polyvinylpyrrolidine is a fine, white to creamy-white colored, odorless or almost
odorless and hygroscopic powder.
 (i) Properties
                Acidity/alkalinity                    :    pH 3.0-7.0 (5% w/v aqueous solution).
                Density (true)                         :    0.409  g/cm3 
                Density (tapped)                     :    0.508   g/cm3
                Density (true)                         :    1.180 g/cm3
                Melting point                         :    soften at 150oC
                Hygroscopicity                       :    it is very hygroscopic. Moisture being
                                                                  absorbed at low Relative humidity.
                Particle size                            :   5% > 200µm in size.
                Dynamic viscosity                  :    10% w/v aqueous solution is 5.5-8.5
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                                                                   5% w/v ethanol is 3.4; 5% w/v on   
                                                                      Propane-2-ol is 5.8.
 (ii) Solubility
               Freely soluble in acids, chloroform, ethanol, ketones, methanol and water;
Practically insoluble in ether, hydrocarbons and mineral oils.
4. Stability and Storage Conditions38
       PVP darkens to extent on heating at 150oC with reduction in aqueous solubility. It
is stable to a short cycle of heat exposure around 110o-130oC. Steam sterilization of an
aqueous solution does not alter its properties.
      Since the powder is hygroscopic, it should be stored in an airtight container in a
cool and dry place. 
LACTOSE, ANHYDROUS 
I.  Synonyms
Anhydrous Lactose NF 60M; Anhydrous Lactose NF Direct Tableting; Lacto
press Anhydrous; lactosum; lattioso; milk sugar; Pharmatose DCL 21.
II.  Empirical Formula and Molecular Weight
C12H22O11  342.30.
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III. Structural Formula
IV.  Functional Category
Binding agent; directly compressible tableting excipient; lyophilization aid; tablet
and capsule filler.
V. Description
Lactose occurs as white to off-white crystalline particles or powder. Several
different  brands  of  anhydrous  lactose  are  commercially  available  which  contain
anhydrous β-lactose and anhydrous α-lactose. Anhydrous lactose typically contains
70–80% anhydrous β-lactose and 20–30% anhydrous α-lactose.
Loss on drying ≤.05%
Angle of repose:
  39° for Pharmatose DCL 21 and 38° for Super-Tab Anhydrous.
Density (true):
  1.589 g/cm3 for anhydrous β-lactose; 1.567 g/cm3 for Super-Tab Anhydrous.
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Density (bulk):
0.68 g/cm3 for  Pharmatose  DCL  21;  0.67 g/cm3 for  Pharmatose  DCL  22;
0.65 g/cm3 for Super-Tab Anhydrous.
Density (tapped):
0.88 g/cm3 for  Pharmatose  DCL  21;  0.79 g/cm3 for  Pharmatose  DCL  22;
0.87 g/cm3 for Super-Tab Anhydrous.
Solubility:  Soluble in water; sparingly soluble in ethanol (95%) and ether.
VI. Applications  in  Pharmaceutical  Formulation  or
Technology
Anhydrous lactose is widely used in direct compression tableting applications
and as a tablet and capsule filler and binder. Anhydrous lactose can be used with
moisture-sensitive drugs due to its low moisture content. 
SODIUM BICARBONATE
Structure:
            Sodium bicarbonate natural mineral form is nahcolite. It is a component of the
mineral natron and  is  found  dissolved  in  many mineral  springs.  It  is  found  in
dissolved form in bile, where it  serves to neutralize the acidity of the hydrochloric
acid produced  by  the  pancreas,  and  is  excreted  into  the duodenum of  the  small
intestine via the bile duct. It is also produced artificially.
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IUPAC name : Sodium hydrogen carbonate
Other names : Baking soda, bicarbonate of soda, break soda, 
sodium bicarbonate, E500,
Functional category : alkalizing agent, Therapeutic agent
Molecular formula : NaHCO3
Molar mass : 84.01 g mol−1
Density : 2.173 g/ cm
Melting point : 50 °C, 323 K, 122 °F (decomposes)
Boiling point : 851 °C, 1124 K, 1564 °F
Solubility : Insoluble in ethanol and ether, soluble in water –
9 g/100 mL, 69 g/L (0 °C), 96 g/l (20 °C), 165 \
g/l (60 °C), 236 g/L (100 °C)
Acidity (pKa) : 10.329- 6.351 (carbonic acid) 
Refractive index : 1.3344
Routes of administration : Intravenous, oral
Description : Sodium bicarbonate is a white solid that 
is crystalline, odourless, but often appears as a
fine powder. It has a slightly salty, alkaline taste
resembling  that  of  washing  soda  (sodium
carbonate). 
Chemistry: Sodium bicarbonate is an amphoteric compound. Aqueous solutions are
mildly alkaline due to the formation of carbonic acid and hydroxide ion:
HCO3 + H2O → H2CO3 + OH−
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Sodium bicarbonate can be used as a wash to remove any acidic impurities
from a "crude" liquid, producing a purer sample. Reaction of sodium bicarbonate and
an acid produce a salt and carbonic acid, which readily decomposes to carbon dioxide
and water:
NaHCO3 + HCl → NaCl + H2CO3
H2CO3 → H2O + CO2 (g)
Sodium  bicarbonate  reacts  with acetic  acid (found  in vinegar),
producing sodium acetate, water, and carbon dioxide:
NaHCO3 + CH3COOH → CH3COONa + H2O + CO2(g)
Sodium  bicarbonate  reacts  with bases such  as sodium  hydroxide to
form carbonates:
NaHCO3 + NaOH → Na2CO3 + H2O
Sodium bicarbonate  reacts  with carboxyl  groups in  proteins  to  give  a brisk
effervescence from the formation of CO2. This reaction is used to test for the presence
of carboxylic groups in protein.
Pharmaceutical applications:
It  is  generally  used  in  pharmaceutical  formulations  as  a  source  of  carbon
dioxide in effervescent tablets and granules it is also used in tablet formulations to
buffer  drug  molecules  that  are  weak  acids,  thereby  increasing  the  rate  of  tablet
dissolution  and  reducing  gastric  irritation.  Recently,  sodium bicarbonate  has  been
used as a  gas  forming systems and in floating oral  controlled release oral  dosage
forms of furosemide and cisapride. 
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 Disintegrating agent
 Neutralizing acids and alkalis
 In cooking
 As antacid in medicine
 Cleaning agent
Stability and storage conditions:
     Sodium bicarbonate powder is stable below 76% relative humidity at 25°C and
below 48% relative humidity at 4°C. Aqueous solutions of Sodium bicarbonate may be
sterilized  by  filtration  or  autoclaving.  To  minimize  decomposition  of  Sodium
bicarbonate  by  decarboxyation  autoclaving,  carbon  dioxide  is  passed  through  the
solution  in  its  final  container,  which  is  than  hermetically  sealed  and  autoclaved
aqueous  solutions  of  sodium  bicarbonate  stored  in  glass  containers  may  develop
deposits of small glass particles. Sodium bicarbonate is stable in dry air but slowly
decomposes in moist air and should therefore be stored in a well closed container in a
cool and dry place.
Incompatibilities:
      Sodium bicarbonate reacts  with acids,  acidic salts,  and many salts, with the
evolution of carbon dioxide.  
TALC
1.   Non-Proprietary names:
 BP: Purified talc
 JP: Talc
 USP: Talc
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2. Synonyms:  Hydrous  magnesium  calcium  silicate,  hydrous  magnesium
silicate,   magnesium hydrogen meta silicate, powdered talc, purified French
chalk, soapstone.
3. Chemical name and CAS registry number: Talc [14807-96-6]
4. Emperical  formula  and  molecular  weight:  Talc  is  a  purified  hydrated
magnesium silicate, approximating to the formula Mg6 (Si2O5)4(OH)4.  It may
contain small, variable amounts of aluminium silicate and iron.
5. Functional category:  Anticaking agent, glidant, tablet and capsule diluent,
tablet and capsule lubricant.
6. Applications in pharmaceutical formulations and technology: 
Table No: 4
S.no Use Concentration (%)
1. Dusting powder 90.0-99.0
2. Glidant and tablet lubricant 1.0-10.0
3. Tablet and capsule diluents 5.0-30.0
7. Description: It is a very fine, white to grayish-white, odourless, impalatable,
unctuous, crystalline powder. It adheres readily to the skin and is soft to touch
and free from grittiness.
8. Typical properties: 
Acidity/alkalinity :    7-10 for a 2-% w/v aqueous dispersion
Hardness :    1.0-1.5
Solubility :    Insoluble in dilute acids and alkalis, organic solvents
      and water.
MAGNESIUM STERATE
Synonyms : magnesium octadecanoate, stearic acid magnesium salt
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Empirical formula : C36 H70 MgO4
Structure: 
Molar mass  :    591.34
Functional category : Tablet and capsule lubricant  
Description : Magnesium Stearate is a fine; white precipitated or 
milled impalpable powder with   low bulk density. The 
powder is greasy to touch and readily adhere to skin.
Bulk density : 0.159 gm/cm
Tapped density : 0.286 gm/ cm
True density : 1.092 gm/cm
Solubility : Slightly soluble in warm ethanol (95%); practically 
insoluble in ether, and water.
Melting range   : 117-150
Applications in pharmaceutical formulation
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It is widely used in cosmetics, foods and pharmaceutical formulations. Primary
use is  as  a  lubricant in  capsule and tablet  manufacturing at  concentration between
0.25 – 5.0%.
Storage conditions: Store in a well closed container in a cool & dry place.
Incompatibility:  Magnesium stearate  is  incompatible  with strongacids,  alkalis  and
iron  salts.  It  cannot  be used  in  products  containing most  alkaloidal  salts.  Aspirin,
certain vitamins and most alkaloidal salts.
Safety: It is widely used as a pharmaceutical excipient and is regarded as non-toxic for
oral administration. Oral consumption in large amount may result in laxative effect or
mucosal irritation.
Handling  precautions: Eye  protection  and  hand  gloves  are  recommended.
Magnesium stearate should be handled in a well- ventilated environment, a respirator
mask is recommended.
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METHODOLOGY
1. Formulation  of  Levetiracetam  floating  tablets  using  different  polymers:
HPMC K4M, HPMC E15, Carbopol 974 p, Sodium Bicarbonate, Magnesium
stearate and Talc in different ratios.
2. FTIR absorption studies have also been carried out for the pure drug and for
drug polymer.
3. Compression of the powders into floating tablets of Levetiracetam. Evaluation
of  floating  tablets  of  Levetiracetam  for  physical  appearance,  hardness,
thickness,  friability,  weight  variation,  content  uniformity  test,  and  in-vitro
buoyancy studies. 
4. In vitro dissolution studies for all the formulations of levetiracetam floating
tablets. 
Materials
A. Procurement of Drug and Excipients:
The  following  materials  and  instruments  used  in  the  experiment  are  of
laboratory grade.
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Table No 5: Details of materials used:
Name of the materials Manufacturer
Levetiracetam Divi’s Laboratories ltd Andhra Pradesh India.
HPMC K4M TAITAN RUITAI Cellulose.co.,ltd.P.R.China
HPMC E15 TAITAN RUITAI Cellulose. co.,ltd.P.R.China
CARBOPOL 974 p Corel pharma chem., gujarat, india.
PVP K30 Nanhang industrial co.,ltd.
Sodium bi carbonate Finar Chemicals Limited, Ahmedabad, India.
Lactose Loba Chemie Pvt.Ltd, Mumbai, India.
Talc Kemphasol, Mumbai, India
Magnesium stearate S.d.fine-Chem Ltd. Mumbai, India
B. INSTRUMENTS AND EQUIPMENTS USED
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Table No 6: Details of equipment used
INSTRUMENTS
S. NO INSTRUMENTS / EQUIPMENTS
MODEL AND MANUFACTURER /
SUPPLIER
1. Digital Balance Shimadzu AX-200 corporation, Japan
2. Electronic Balance Schimadzu corporation, Japan
3. UV-Visible Spectrophotometer UV-1700  Shimadzu  corporation,
Japan
4. Rotary compression machine Cadmach, india.
5. Friabilator EF-2 Friabilator, Electro lab, Mumbai
6. Hardness tester Pfizer  hardness  tester,  Servewell
instruments and equipments Pvt. Ltd.,
Bangalore.
7. Dissolution apparatus Electrolab  TDT 08 Dissolution tester
USP
8. Digital pH meter 7007, Digisun electronics, Hyderabad
9. Glass ware Borosil, Chennai.
10 FTIR Shimadzu, japan
6.2 METHODS
6.2.1 Analytical Study
UV Spectroscopic method for analysis of Levetiracetam:
Preparation of 0.1 N Hydrochloric acid:
8.5ml of Concentrated HCl was taken in a volumetric flask and it was made up to
1000ml with distilled water.
Preparation of Stock solution
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Weighed  accurately  100mg  of  Levetiracetam pure  drug  was  dissolved  in
100ml of 0.1N HCL (stock solution) (1000µg/ml).10ml of solution was taken and
make up with100ml of 0.1N HCL (100µg/ml). 
Preparation of Standard solution
The above solution was subsequently diluted with 0.1N HCl to obtain series of
dilutions containing 20,40,60,80 and 100µg/ml of Levetiracetam per ml of solution. 
• The absorbance of the above dilutions was measured at  210 nm by
using UV-Spectrophotometer taking 0.1N HCl as blank. 
• Then  a  graph  was  plotted  by  taking  concentration  on  X-Axis  and
absorbance on Y-axis which gives a straight line.    
Table No 7: Calibration curve of Levetiracetam in 0.1N HCl (pH1.2) λmax 210 nm
S.no. Concentration  (µg/ml) Absorbance
1 0 0
2 20 0.2028
3 40 0.4092
4 55.5 0.5629
5 60 0.6102
6 80
0.8117
7 100 1.0162
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CHAPTER VI                                                                                                                                      METHODOLOGY
PREFORMULATION STUDY
6.3. PREFORMULATION
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Preformulation testing is an investigation of physical and chemical properties
of a drug substance alone and when combined with excipients. It is the first step in the
rational development of dosage forms. Preformulation studies relate to pharmaceutical
and analytical investigation carried out in supporting formulation development efforts
of the dosage  form. The following Preformulation studies were  performed for  the
obtained sample of drug.  
6.3.1. Physical characteristics:
6.3.1.1. Flow properties: 39
The flow properties of powders are critical for an efficient tabletting operation.
A  good  flow  of  powder  or  granulation  to  be  compressed  is  necessary  to  assure
efficient missing and acceptable weight uniformity for the compressed tablets.  If a
drug is identified at the pre formulation stage to be “poorly flowable”, the problem
can be solved by selecting appropriate excipients.  In some cases, drug powders may
have to be pre-compressed or granulated to improve their flow properties.  During pre
formulation  evaluation  of  drug  substance,  therefore,  its  flowability  characteristic
should be studied, especially when the anticipated dose of the drug is large. Angle of
repose is defined as the maximum angle possible between the surface of a pile of the
powder and the horizontal plane.
Procedure:
A funnel was kept vertically in a stand at a specified height above a paper
placed on a horizontal surface.  The funnel bottom is closed and 10 gm of sample
powder is filled in funnel.   Then funnel was opened to release the powder on the
paper to form a smooth conical heap, is found by measuring in different direction.
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The height of the heap was measured by using scale.  The values of angle of repose
are calculated by using the following formula:  
Tan θ = h/r        
θ = tan -1 (h/r)
Where, θ – angle of repose
h- Height of the heap 
            r - Radius of the heap 
Table No 8: Angle of repose limits
Angle of repose Flowability
<25 Excellent
25-30 Good
30-40 Passable
>40 Very poor
The results are shown in Table 14.
6.3.1.2 Bulk density
Bulk density is the ratio of mass of powder to the bulk volume. Bulk density
largely depends on particle shape, as the particles become more spherical in shape,
bulk density is increase. In addition as granules size increase, bulk density decrease.
Bulk density is determined by measuring the volume of a known mass of powder
sample that has been passed through a screen into a graduated cylinder.
Procedure:
A known quantity of powder was poured into the measuring cylinder carefully
level the powder without compacting, if necessary and read the unsettled apparent
volume. Calculate the bulk density, in gm per ml, by the formula
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(ρb) = m / Vb.
Where, ρb =Bulk Density 
m = mass of powder
           Vb = initial / bulk volume
The results are shown in Table 14.
6.3.1.3. Tapped density:
Tapped density is the ratio of mass of powder to the tapped volume.
Procedure:
A quantity of 5g of the powder (W) from each formula was introduced into a
25 ml measuring cylinder. After the initial volume was observed, the cylinder was
allowed to fall under its own weight onto a hard surface from the height of 2.5 cm at 2
sec intervals. The tapping was continued until no further change in volume was noted.
Calculate the tapped density, in gm per ml, by the formula:
(ρt)= m/Vt
Where, ρt =Tapped Density
m = mass of powder
 Vt= final / tapped volume
6.3.1.4 Measurement of Powder Compressibility: 
Compressibility  Index  is  measure  of  the  propensity  of  a  powder  to  be
compressed. As such, they are measures of the relative importance of inter particulate
interactions. In a free flowing powder, such interactions are generally less and tapped
densities will be closer in value. 
For  poorer  flowing  materials,  there  are  frequently  greater  inter  particle
interactions,  and  a  greater  difference  between  bulk  and  tapped  densities  will  be
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observed. These differences are reflected in the compressibility Index Calculated by
the formula,
       Tapped density - Initial bulk density
% Compressibility   =   ————————————————— x 100
      (Carr’s index)                             Tapped density                          
                
Table No 9: Compressibility index limits
%Compressibility Flowability
5-12 Excellent
12-16 Good
18-21 Fair
23-25 Poor
33-38 Very poor
more than 40 Very, very poor
6.3.1.5 Hausner’s Ratio:
It is the ratio of volume of tapped volume or tapped density to bulk density
Hausner’s Ratio =  Vb/Vt or ρt /ρb.
Table No 10: Hausner’s Ratio index limits.
Hausner’s Ratio Flowability
1.2-1.3 Excellent
1.3-1.4 Good
1.4-1.5 Fair
1.3-1.4 Poor
6.4. Identification of drug and compatibility study:
6.4.1. Drug - Excipient Compatibility Studies 40
In  the tablet dosage form the drug is in intimate contact  with one or more
excipients;  the  latter  could  affect  the  stability  of  the  drug.   Knowledge  of  drug-
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excipient  interactions  is  therefore  very  useful  to  the  formulator  in  selecting
appropriate excipients. This information may already be in existence for known drugs.
For  new drugs  or  new excipients,  the  pre  formulation scientist  must  generate  the
needed information.
By Physical observation
It  was determined as per procedure given in method section. The following
table illustrated the result.
Table No 11: Physical Compatibility Studies
Test Observations Inference
Physical
compatibility
No change of color
These  materials  are  compatible  for
formulations.
Procedure by IR Studies 41,42
The  IR  spectrums  of  the  Levetiracetam  with  excipients  were  taken  by
preparing dispersion in dry potassium bromide under dry condition. Obtained spectra
were  superimposed.  The transmission  minima (absorption  maxima)  in  the  spectra
obtained with the sample corresponded in position and relative size to those in the
spectrum obtained with the standards.
6.5 Preparation of tablets
Preparation of levetiracetam Floating Tablets
              Twelve formulations of floating tablets of levetiracetam using the polymer of
different grades namely Hydroxy Propyl Methyl Cellulose K4M (HPMC K 4 M), and
Hydroxy Propyl Methyl Cellulose E15 (HPMC E15) in different concentrations were
prepared  by  wet  granulation  method.  Sodium  bicarbonate  was  used  as  a  gas
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generating agent. Polyvinyl Pyrrolidine (PVP K30) is used as solubilizer enhancing
agent. Lactose is used as a diluent.
           Twelve formulations of levetiracetam were prepared.  Pure levetiacetam,
sodium  bicarbonate,  HPMC  K4M,  HPMCE15  and  carbopol  974P  with  different
concentrations,  Polyvinyl  Pyrrolidone  (PVP  K30),  sodim bicarbonate  and  lactose
were mixed together in mortar and pestle to get uniform mixture. Now the blended
powder was passed through sieve no. 60.  Granules  were prepared using isopropyl
alcohol  as  a  solvent.  Prepared  granules  were  dried  at  tray drier.  After  drying  the
granules  were  passed  through  sieve  no;  22.  The  dried  granules  was  subjected  to
different preformulation studies namely Bulk density, Tapped Density and Angle of
Repose.  After  that  the  granules  was  mixed  with  talc  and  magnesium  stearate
uniformily  and  then  compressed  into  tablets  by  compression.All  the  formulations
were prepared by wet granulation method. The compressions of different formulations
are given in Table -The tablets were prepared as per the procedure given above and
the aim is to controlled the release of Levetiracetam floating tablets.
Table No 12: Composition of gastro-retentive tablets of Levetiracetam (in mg)
Ingrediants F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12
Levetiracetam 500 500 500 500 500 500 500 500 500 500 500 500
HPMC K4M 50 100 50 50 50 50 ---- ---- 50 50 50 ----
HPMC E15 150 150 200 150 150 150 150 150 0 0 ---- ----
Carbopol 974 p ---- ---- 0 0 0 ---- 100 150 100 150 150 150
Sodium  Bi
Carbonate
100 100 100 50 100 150 100 100 100 100 100 100
Lactose 0 0 0 0 100 0 0 0 0 0 100 0
PVP k30 q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s
Magnesium
Stearate
5 5 5 5 5 5 5 5 5 5 5 5
Talc 10 10 10 10 10 10 10 10 10 10 10 10
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Total weight 815 865 865 765 915 865 865 915 765 815 915 765
6.6. EVALUATION OF TABLETS
The  formulated  tablets  were  evaluated  for  the  following  physicochemical
characteristics: 
6.6.1 General appearance:  
The  formulated  tablets  were  assessed  for  its  general  appearance  and
observations were made for shape, color, texture and odor.   
6.6.2 Hardness test: 43
Hardness of the tablet was determined by using the Monsanto hardness tester
(n=3or5) the lower plunger was placed in contact with the tablet and a zero reading
was taken. The plunger was then forced against a spring by turning a threaded bolt
until the tablet fractured. As the spring was compressed a pointer rides along a gauge
in the barrel to indicate the force. 
6.6.3 Thickness of tablets                       
            The tablets should have uniform thickness. Thickness was measured by using
vernier  calipers.  To  get  required  thickness  before  compression  these  values  are
checked and adjusted.
6.6.4 Weight variation44:
20  tablets  were  selected  at  random  and  weighed   individually.  From  the
collective  weight,  average  weight  was  calculated.  Each  tablet  weight  was  then
compared with average weight to ascertain whether it was within permissible limits or
not.  
6.6.5 Uniformity of weight: 
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The  values  of  average  weight  are  given  in  below the  table  10  and  are  in within 
 limit
   Perce
ntage
Deviation      =  
Individual weight –  Average weight 100
Average weight
´
Table No.13
6.6.7 Friability test: 45
20 previously weighed tablets were placed in the apparatus. Which was given
100  revolutions  and  the  tablets  were  reweighed.  The  percentage  friability  was
calculated by using the following formula, 
Percentage friability = (initial weight - final weight) / initial weight × 100. 
6.6.8 Drug content: 46
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1 <80mg 10
2 80 – 250 mg 7.5
3 >250mg 5
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Twenty tablets  of  each formulation were  weighed,  powdered  about  100mg
equivalent  levetiracetam  was  transferred  into  a  100ml  volumetric  flask  and  the
volume was made up with 0.1N HCL. A suitable volume of this was then diluted with
0.  1N  HCL  to  get  a  appropriate  concentration,  then  filtered  through  0.45  µm
whatmann filter  paper, the absorbance  of  resulting solution was analysed  by UV-
Visible spectrophotometer at a maximum of about 210nm using 0.1N HCL as blank
solution.
5.6.9 In vitro Buoyancy studies: 47,48
The buoyancy tablet  was studied at 37±0.5⁰c.  The tablets were placed in a
100ml beaker containing 0.1N HCL. The time required for the tablet to rise to the
surface of the liquid to float was determined as the Buoyancy Lag Time (BLT) or
Floating Lag Time (FLT) and the duration of time of the tablet constantly floating on
the dissolution medium was noted as total floating time (TFT).
5.6.10 Buoyancy Determination49
i. Buoyancy Lag Time (BLT) :-    The time interval  between the introduction of
Levetiracetam floating tablets in to the dissolution medium and its flotation to the top
of dissolution medium was termed as BLT.
BLT may be explained as a result of time required for dissolution medium to
penetrate  the  tablet   and  develop  the  swollen  layer  for  the  entrapment  of  CO2
generating in situ. The tablet mass decreased progressively due to liberation of CO2
and release of drug from the tablet.
ii. Duration of Buoyancy  (DB):- The duration upto which the dosage form floats
over the dissolution medium was termed as DB.
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 Duration of buoyancy of tablet depends on the amount of sodium bicarbonate
involved in CO2 formation, for a floating system.  In order to intiate rapid generation
of CO2 and allowed to release CO2 to promote floating, the ideal tablet  of coating
material should be highly permeable.
Method :  The buoyancy lag time and duration of buoyancy were carried using USP
24 type II dissolution apparatus in 900 ml of 0.1N Hcl at 37 ± 1 oC   
vii) swelling index50
The swelling index studies were carried out in petri  dishes using simulated
gastric  fluid  (pH  1.2).The  randomly  selected  tablets  from  each  formulation  were
weighed individually (W0 ) and placed separately in 50 ml of simulated gastric fluid
(pH 1.2) in petri dish. After 8 hours swollen tablet was removed from the medium the
excess  water  was  blotted  with  filter  paper  and  immediately  weighed  (w1).  The
swelling index (SI), expressed as a percentage and was calculated from the following
equation
1 2
0
W -WSI =  × 100
W
5.7 IN VITRO DISSOLUTION STUDIES OF TABLETS:
5.7.1 Dissolution parameters:
Apparatus  -- USP-II, Paddle Method
Dissolution Medium --  0.1 N HCl (pH 1.2)
RPM  -- 50 rpm
Temperature -- 37°c + 0.5°C
5.7.2 Dissolution Study:
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The floating tablets were evaluated for dissolution rate in 0.1 N HCl (pH 1.2).
Procedure: 51
The release of levetiraceatm from the tablets was studied by using USP 29
paddle apparatus. Drug release profile was carried out in 900ml of freshly prepared
0.1N HCL maintained at 37 ± 0.5ºC as a medium and rotating the paddles at 50rpm.
At each sampling interval, 10 ml of the sample was withdrawn and replaced by an
equal volume of 0.1 N HCl. The samples were filtered through whatmann filter paper
and  analyzed  after  appropriate  dilution  by  using  UV  spectrophotometer.  The
absorbance of the sample solution was measured at the maximum wavelength of 210
nm. Cumulative percentage of drug release was calculated using the equation obtained
from the standard curve. 
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The present study was to formulate Levetiracetam floating tablets  in twelve
different batches F1 to F12 using polymer Hydroxy propyl methyl cellulose of two
different grades (HPMC K15 M and HPMC K4 M) and carbopol 974 p in different
concentrations. All the formulations were prepared by wet granulation method. The
granules  were  subjected  to  IR  spectral  analysis.   The  granules  were  taken  for
preformulation  studies  such  as  Bulk  density,  Tapped  density,  Angle  of  repose,
Compressibility  index  and  Hausner  ratio  and  tabulated  in  table  no  14.  After
compression, evaluation tests of tablet such as hardness, weight variation, friability,
buoyancy determination, swelling index and content uniformity is done. Finally the
tablets were evaluated for invitro-drug release. 
Evaluation of levetiracetam granules
Bulk density
By  using  measuring  cylinder  the  bulk  density  of  all  formulations  was
measured. The bulk density was found in the range of 0.3236-0.3867. It is within the
acceptable limits.
 Tapped density
Tapped density  of  all  formulations    measured  by measuring cylinder  and
values were determined. The tapped density was found in the range of 0.3905-0.4724
gm/cm3.  It showed that tapped density is within the acceptable limit.
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Angle of Repose
For all the formulations angle of repose were found within 30.240, granules
indicates  good  flow  property.  The  results  showed  that  the  flow  properties  of  all
formulations are good 22.410 to 30.240
Compressibility Index
The granules show good flow character, since the compressibility index of all
the formulation is between 11-15. 
Hausner Ratio
         Hausner ratio of all the formulations were between 1.12-1.18. If the Hausner
ratio  lies  between  1.13-1.27,  it  indicates  good  flow  behavior  of  the  granules  or
powder. The results indicates the granules possess good flow property.     
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BATCH
NO
Bulk density
(gm/cm3 )
Tapped
density
(gm/cm3 )
Carr’s index
(IC )
Hausner
ratio
(HR )
Angle of
repose
F1 0.3423 0.4156 12.14 1.21 25.40°
F2 0.3684 0.4226 11.47 1.14 28.82°
F3 0.3354 0.3905 11.64 1.26 26.7°
F4 0.3741 0.4724 12.62 1.18 29.84°
F5 0.3566 0.4241 11.89 1.18 22.41°
F6 0.3654 0.4421 12.09 1.120 24.25°
F7 0.3346 0.4133 12.35 1.23 28.48°
F8 0.3542 0.4491 12.67 1.26 26.92°
F9 0.3285 0.4198 12.77 1.27 30.24°
F10 0.3236 0.4165 12.12 1.21 29.82°
F11 0.3398 0.3956 11.64 1.16 24.56°
F12 0.3867 0.4379 11.32 1.13 22.48°
 Table no:14
Evaluation of Levetiracetam Floating Tablets
The  evaluated levetiracatm Floating tablets were evaluated and the results are
shown in table no15.
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 The hardness of the tablets were tested by using Mosanto hardness tester, and
the results are tabulated in the Table-15. The hardness of the tablets of all
formulations were within the range of 4.0-4.8 Kg/cm2. 
 Tablet mean thicknesses  were almost uniform in all formulations and were
found to be    in the range of 3.38 to 3.79mm. (Table no15.)
 Friability  value  was  found  to  be  less  than  1%  and  considered  to  be
satisfactory.(Table no15.)
 All this tablets passed weight variation test as the % weight variation was
within the pharmacopoeia limits. The weight of the all tablets was found to be
uniform with low standard deviation values.(Table no15.)
 Drug content was within the acceptable range which shows the proper mixing
of the drug with the excipients.
 Swelling Index:  Swelling Index  of  the polymers  can  be measured  by their
ability to absorb water and swell  enormously.  Swelling Index is  within the
range of 51.17-96.23%
Table no:15
Batch
no
Average
wt
Thickness
(mm)
Hardness
(kg/cm2)
Friability
(%)
Swelling
index
Drug
content
DEPARTMENT OF PHARMACEUTICS,A.K.COLLEGE OF PHARMACY   73
             	 
        	   
 	 	   
(mg) (%) (%)
F1 816±1.14 3.5±0.04 4.5±0.02 0.28% 52.24% 98.26%
F2 864±0.70 3.6±0.06 4.2±0.08 0.3% 88.03% 99.08%
F3 866±0.83 3.7±0.04 4.5±0.02 0.25% 72.93% 97.96%
F4 763±1.14 3.39±0.01 4±0.07 0.21% 63.94% 101.17%
F5 912±1.16 3.79±0.08 4.7±0.015 0.32% 65.41% 98.48%
F6 866±0.83 3.71±0.01 4.5±0.20 0.2% 61.48% 98.74%
F7 868±1.14 3.7±0.04 4.5±0.20 0.25% 76.58% 98.53%
F8 914±0.83 3.77±0.01 4.8±0.15 0.28% 85.11% 100.07%
F9 763±0.89 3.4±0.04 4.1±0.05 0.22% 73.56% 99.24%
F10 814±0.83 3.5±0.04 4.3±0.13 0.26% 51.17% 97.41%
F11 912±0.83 3.78±0.01 4.5±0.20 0.29% 96.23% 96.84%
F12 768±1.30 3.38±0.01 4.3±0.07 0.24% 77.00% 98.74%
Buoyancy Determination 
i) Buoyancy Lag Time (BLT) :  
Buoyancy lag time were determined by using dissolution apparatus at 50 rpm
using  900ml  pH  1.2  buffer  and  temperature  was  maintained  at  370C  ±  0.50C
throughout  the study.  The Buoyancy Lag  Time is  in  between  40-780 sec for  all
formulations. F6 alone had buoyancy lag time more than 15 minutes.
ii) Duration of Buoyancy (DB):   
Duration of buoyancy (DB) is the time that the tablet floats in the dissolution
medium. Duration of Buoyancy (DB) of all the formulations is more than 12 hours,
except F12, F8 and F7.   
Table no:16
FORMULATION
BUOYANCY LAG TIME
(SEC.)
DURATION OF BUOYANCY(Hrs.)
F1 540 Sec >12
F2 600 Sec >12
F3 624 Sec >12
F4 240 Sec >12
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F5 600 Sec >12
F6 1500 Sec >12
F7 780 Sec <12
F8 780 Sec <12
F9 40 Sec >12
F10 60 Sec >12
F11 560 Sec >12
F12 120 Sec <12
INFRARED SPECTRAL STUDIES
The results of the IR spectra studies are presented in figure 1,2,3,4,5,6,7.
                 The IR spectrum of drug-polymer shows that there is no specific interaction
between  Levetiracetam  and  hydroxyl  propyl  methyl  cellulose  (HPMCK4M
&E15),and Carbopol 974p.
                The primary amino  group(NH2) peak of levetiracetam is seen clearly at
around 3360 cm-1 in the spectra of mixed formulations.
                  The C-N Heterocyclic peak is observed at 2360cm-1  in both levetiracetam
spectra and spectra of mixed formulation.
                   Based on the above IR spectra, there is no significant interaction between
drug & polymer as evidenced by the presence of bonds due to the responding reactive
functional groups.
DISSOLUTIONS STUDIES 
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The  Dissolution  rate  studies  were  performed  to  evaluate  the  dissolution
characteristic  of levetiracetam from floating tablets  with twelve formulations were
prepared. The drug release of twelve formulations were compared with each other.
The results are presented in table 17 to 28 . From the invitro drug release studies the
T50% T70% T90% were calculated and the results were depicted in the table no29.
Cumulative percentage of drug  release from the tablets
Table no:17
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Time FORMULATION -1
0 0
1 hr 11.45%
2 hrs 23.35%
3 hrs 29.45%
4 hrs 38.76%
5 hrs 45.25%
6 hrs 52.55%
7 hrs 59.85%
8 hrs 64.75%
9 hrs 72.23%
10hrs 79.45%
11hrs 84.25%
12hrs 93.5%
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Fig. : Percent Drug Released Vs Time Plots of formulations F 1
Table no:18
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TIME FORMULATION -2
0 0
1 hr 13.25%
2 hrs 20.98%
3 hrs 26.51%
4 hrs 31.96%
5 hrs 37.65%
6 hrs 44.12%
7 hrs 53.75%
8 hrs 59.92%
9 hrs 67.85%
10hrs 72.35%
11hrs 78.16%
12hrs 84.7%
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Fig. : Percent Drug Released Vs Time Plots of formulations F 2
Table no:19
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TIME FORMULATION -3
0 0
1 hr 23.13%
2 hrs 31.06%
3 hrs 42.16%
4 hrs 49.59%
5 hrs 55.23%
6 hrs 60.95%
7 hrs 64.72%
8 hrs 70.79%
9 hrs 74.65%
10hrs 78.3%
11hrs 81.45%
12hrs 86.75%
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Fig. : Percent Drug Released Vs Time Plots of formulations F 3
Table no:20
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TIME FORMULATION -4
0 0
1 hr 9.55%
2 hrs 19.9%
3 hrs 25.48%
4 hrs 31.65%
5 hrs 38.25%
6 hrs 46.45%
7 hrs 49.25%
8 hrs 56.18%
9 hrs 62.55%
10hrs 69.85%
11hrs 79.7%
12hrs 88.55%
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Fig. : Percent Drug Released Vs Time Plots of formulations F 4
Table no:21
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TIME FORMULATION -5
0 0
1 hrs 8.56%
2 hrs 15.6%
3 hrs 27.32%
4 hrs 39.75%
5 hrs 56.32%
6 hrs 61.2%
7 hrs 67.38%
8 hrs 74.6%
9 hrs 78.72%
10hrs 83.68%
11hrs 89.25%
12hrs 95.05%
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Fig. : Percent Drug Released Vs Time Plots of formulations F 5
Table no:22
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TIME FORMULATION -6
0 0
1 hrs 10.16%
2 hrs 21.58%
3 hrs 27.45%
4 hrs 33.42%
5 hrs 49.48%
6 hrs 54.48%
7 hrs 61.25%
8 hrs 68.58%
9 hrs 76.95%
10hrs 82.35%
11hrs 88.75%
12hrs 94.8%
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Fig. : Percent Drug Released Vs Time Plots of formulations F 6
Table no:23
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TIME FORMULATION -7
0 0
1 hrs 39.87%
2 hrs 48.73%
3 hrs 57.82%
4 hrs 67.76%
5 hrs 77.65%
6 hrs 84.96%
7 hrs 98.92%
8 hrs -
9 hrs -
10hrs -
11hrs -
12hrs -
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Fig. : Percent Drug Released Vs Time Plots of formulations F 7
Table no:24
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TIME FORMULATION -8
0 0
1 hrs 27.57%
2 hrs 35.65%
3 hrs 52.5%
4 hrs 65.45%
5 hrs 75.36%
6 hrs 81.94%
7 hrs 98.78%
8 hrs -
9 hrs -
10hrs -
11hrs -
12hrs -
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Fig. : Percent Drug Released Vs Time Plots of formulations F 8
Table no:25
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TIME FORMULATION -9
0 0
1 hrs 10.3%
2 hrs 16.38%
3 hrs 23.7%
4 hrs 30.48%
5 hrs 41.59%
6 hrs 48.7%
7 hrs 54.5%
8 hrs 68.05%
9 hrs 79.1%
10hrs 84.72%
11hrs 95.14%
12hrs 98.67%
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Fig. : Percent Drug Released Vs Time Plots of formulations F 9
Table no:26
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TIME FORMULATION -10
0 0
1 hrs 7.25%
2 hrs 11.55%
3 hrs 19.31%
4 hrs 25.85%
5 hrs 32.25%
6 hrs 43.38%
7 hrs 52.75%
8 hrs 64.67%
9 hrs 72.35%
10hrs 85.7%
11hrs 96.55%
12hrs 98.36%
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Fig. : Percent Drug Released Vs Time Plots of formulations F 10
Table no:27
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TIME FORMULATION -11
0 0
1 hrs 27.57%
2 hrs 41.24%
3 hrs 51.44%
4 hrs 61.2%
5 hrs 68.65%
6 hrs 77.25%
7 hrs 81.71%
8 hrs 85.95%
9 hrs 89.75%
10hrs 92.1%
11hrs 95.13%
12hrs 97.28%
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Fig. : Percent Drug Released Vs Time Plots of formulations F 11
Table no:28
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TIME FORMULATION -12
0 0
1 hrs 44.31%
2 hrs 59.82%
3 hrs 78.74%
4 hrs 84.5%
5 hrs 92.36%
6 hrs 99.74%
7 hrs -
8 hrs -
9 hrs -
10hrs -
11hrs -
12hrs
-
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Fig. : Percent Drug Released Vs Time Plots of formulations F 12
Table no:29
Formulations                                 Parameters
T50% (Mints) T70% (Mints) T90% (Mints)
F1 348 528 702
F2 408 576 0
F3 252 480 0
F4 432 606 0
F5 282 444 672
F6 312 498 678
F7 138 258 384
F8 174 276 396
F9 356 492 636
F10 414 528 624
F11 174 318 570
F12 90 156 282
The floating tablet of levetiracetam was designed to retend the drug for a time
interval  of minimum 12 hrs which will enhance the bioavailability as well as will
extend the duration of action of the nootropic drug. Toward this approach the tablet
was formulated using different polymers such as HPMC K4M, HPMC E15, Carbopol
974 P. Further the effect of gas forming agent NaHCO3 on the buoyancy of the tablet
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was also studied. The results indicated that the tablets from the batch F2 produced a
maximum retardant effect and a buoyancy time which is higher than 24 hours. The
formulation  F12 produced a least retardant effect which was evident from the invitro
drug release profile showing t50%,   t70%, and  t90%of 90 mins, 156 mins and 282 mins
respectively. The buoyancy time also was found to be only 6 hrs for the batch F12.
The formulation F2 produced the maximum retardant effect and buoyancy time was
composed of Levetiracetam 500 mg, HPMC K4M 100mg, HPMC E15 150mg, and
NaHCO3 100mg. while F3 composed of higher  HPMC E15 and lower HPMC K4M
quantities revealed a less retardant effect than F2 suggesting that the ability to retard
the release of the drug mainly rely on the polymer HPMC K4M rather than HPMC
E15 and also the buoyancy time was found to be lower than the formulation F3. The
formulation F4 also revealed the aforementioned hypothesis, which was evident from
its invitro data and buoyancy time. The formulation F4 showed a comparable higher
invitro drug release resulting due to the decrease of quantity of sodium bicarbonate
leading to decreased buoyancy time. This effect might have been caused by the less
amount of CO2 produced which in turn makes it less porous and higher denser and
hence resulting in reduction of floating time which has initiated a higher drug release.
The formulation F1 with a higher quantity of sodium carbonate invitro drug release
also  strengthens  the  aforementioned  conclusion.  The  formulation  F5  incorporated
with lactose also decreased the t50%,  t70%, and  t90%  values and this can be attributed to
the solubility of lactose in the dissolution medium and hence enhance the penetration
of the dissolution medium resulting in faster release of the drug. The formulations F
11, F10, F9 and F8 were incorporated with the swellable water insoluble gel forming
polymer Carbopol 974P. Carbopol 974 P forms water insoluble gel into which the
drug  is  entrapped  resulting  in  supersaturation  of  drug  inside  it.  This  results  in
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enhanced solubility and further leeching of the drug into the drug dissolution medium
which  is  evident  from  the  invitro  drug  release  studies.  Further  when  the  drug
levetiracetam is depleted from the tablet it results in the formation of pores ending up
in the increased erosion of the tablet. This is evident from the buoyancy time of the
formulations incorporated with carbopol. 
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CHAPTER VIII                                                                                                   SUMMARY AND CONCLUSION
SUMMARY
The objective of present study was to develop floating tablets of levetiracetam
in order to achieve an extended retention in the stomach and thereby increase the
bioavailability and study the release characteristics with twelve formulations.
The  formulation  was  done  by  wet  granulation  method  and  the  granules
prepared  were  evaluated  for  the  preformulation  parameters  such  as  bulk  density,
tapped density, angle of repose, carr’s index and hausner ratio.
Tablets were prepared by wet granulation method. Tablets were evaluated for
their  physiochemical  properties  like  angle  of  repose,  hardness,  friability,  weight
variation, thickness, compressibility studies, etc.
Tablets were then subjected to in-vitro release in pH 1.2 gastric stimulating the
pH of stomach for about 12 hours using dissolution apparatus.The dissolution profiles
for  the  formulation  showed  an  initial  burst  release  followed  by  controlled  and
sustained release.
CONCLUSION
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From the above results  obtained  it  can be  concluded that  the  formulations
possessing higher concentration of HPMC K4M possess good retardant effect of the
drug  levetiracetam  and  also  increase  the  residence  of  the  drug  indicated  by  its
increased buoyancy time. In particular batch F2, with HPMC K4M 100MG, HPMC
E15 150 mg,  sodium bicarbonate  100  mg  and  levetiracetam  500 mg has  a  good
retardant and retention effect.  The formulations incorporated with lactose, carbopol
enhanced the leeching of the drug from the tablet gel matrix. However the batch F2
has fulfilled the objectives of our study and can be satisfactorily used for increasing
patient compliance.
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CHAPTER                                                                                                                                                  COMPATIBILITY STUDY
LEVETIRACETAM FLOATING TABLETS
Drug Excipient compatibility study: 
Drug : 
Excipient
Ratio Stability 
condition
Imp
A
(%)
Imp 
B
(%)
Imp 
C
(%)
Imp
 D
(%)
Unkn
own 
Imp
Total 
Imp
API -
INITIAL ND ND ND 0.02 ND 0.02
40°C/75%RH-
1M ND ND ND 0.02 ND 0.02
40°C/75%RH-
2M ND ND 0.01 0.03 0.01 0.05
40°C/75%RH-
3M ND ND 0.01 0.03 ND 0.04
50°C/90%RH-
1M ND ND ND 0.02 ND 0.02
API + HPMC
K4M 1 : 1
INITIAL ND ND 0.01 0.02 ND 0.03
40°C/75%RH-
1M ND ND 0.01 0.02 ND 0.03
40°C/75%RH-
2M ND ND 0.01 0.03 ND 0.04
40°C/75%RH-
3M ND ND 0.01 0.02 0.02 0.05
50°C/90%RH-
1M ND ND ND 0.02 ND 0.02
API + HPMC
E 15 1 : 1
INITIAL ND ND 0.01 0.03 ND 0.04
40°C/75%RH-
1M ND ND ND 0.02 ND 0.02
40°C/75%RH-
2M 0.01 ND 0.01 0.03 ND 0.05
40°C/75%RH-
3M ND ND 0.01 0.02 0.02 0.05
50°C/90%RH-
1M 0.01 ND ND 0.02 ND 0.03
API +
Carbopol 974 p 1 : 1
INITIAL ND ND 0.01 0.03 ND 0.04
40°C/75%RH-
1M ND ND 0.01 0.02 0.01 0.04
40°C/75%RH-
2M ND ND 0.01 0.03 ND 0.04
40°C/75%RH-
3M ND ND 0.01 0.03 ND 0.04
50°C/90%RH-
1M ND ND ND 0.02 ND
0.02
INITIAL ND ND ND 0.02 ND 0.02
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API + sodium
bicarbonate 1 : 1
40°C/75%RH-
1M ND ND 0.01 0.03 ND 0.04
40°C/75%RH-
2M ND ND 0.01 0.03 ND 0.04
40°C/75%RH-
3M ND ND 0.01 0.03 ND 0.04
50°C/90%RH-
1M ND ND 0.01 0.03 ND 0.04
API + Lactose 1 : 1
INITIAL ND ND 0.01 0.03 ND 0.04
40°C/75%RH-
1M ND ND 0.01 0.02 0.01 0.04
40°C/75%RH-
2M ND ND 0.01 0.03 ND 0.04
40°C/75%RH-
3M ND ND 0.01 0.03 ND 0.04
50°C/90%RH-
1M ND ND ND 0.02 ND 0.02
API + PVPK30 1 : 1
INITIAL ND ND 0.01 0.03 ND 0.04
40°C/75%RH-
1M ND ND ND 0.02 0.01 0.03
40°C/75%RH-
2M ND ND ND 0.02 0.01 0.03
40°C/75%RH-
3M ND ND 0.01 0.03 ND 0.04
50°C/90%RH-
1M ND ND ND 0.02 ND 0.02
API + Talc -
INITIAL ND ND ND ND ND 0
40°C/75%RH-
1M ND ND ND ND ND 0
40°C/75%RH-
2M ND ND ND ND ND 0
40°C/75%RH-
3M ND ND ND 0.01 ND 0.01
50°C/90%RH-
1M ND ND ND ND ND 0
API +
Magnesium
stearate
-
INITIAL ND ND ND ND ND 0
40°C/75%RH-
1M ND ND ND ND ND 0
40°C/75%RH-
2M 0.01 ND ND ND ND 0.01
40°C/75%RH-
3M ND ND ND ND ND 0
50°C/90%RH-
1M ND ND ND ND ND
0
HPMC K 4M INITIAL ND ND ND ND ND 0
40°C/75%RH-
1M ND ND ND ND ND 0
40°C/75%RH-
2M
ND ND ND ND ND 0
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40°C/75%RH-
3M ND ND ND ND 0.01 0.01
50°C/90%RH-
1M ND ND ND ND ND 0
HPMC E15 - INITIAL ND ND ND ND ND 0
40°C/75%RH-
1M ND ND ND ND ND 0
40°C/75%RH-
2M ND ND ND ND ND 0
40°C/75%RH-
3M ND ND ND ND ND 0
50°C/90%RH-
1M ND ND ND ND ND 0
Carbopol974p - INITIAL ND ND ND ND ND 0
40°C/75%RH-
1M ND ND ND ND ND 0
40°C/75%RH-
2M ND ND ND ND ND 0
40°C/75%RH-
3M ND ND 0.01 ND ND 0.01
50°C/90%RH-
1M ND ND ND ND ND 0
Sodiumbi 
carbonate
-
INITIAL ND ND ND ND ND 0
40°C/75%RH-
1M ND ND ND ND ND 0
40°C/75%RH-
2M ND ND ND ND ND 0
40°C/75%RH-
3M ND ND ND 0.01 ND 0.01
50°C/90%RH-
1M ND ND ND ND ND 0
Lactose -
INITIAL ND ND 0.01 0.02 ND 0.03
40°C/75%RH-
1M ND ND ND 0.02 0.01 0.03
40°C/75%RH-
2M 0.01 ND 0.01 0.03 ND 0.04
40°C/75%RH-
3M 0.02 ND 0.01 0.02 0.03 0.08
50°C/90%RH-
1M 0.04 ND ND 0.02 0.01 0.03
PVP - INITIAL ND ND ND ND ND 0
40°C/75%RH-
1M ND ND ND ND ND 0
40°C/75%RH-
2M ND ND ND ND ND 0
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40°C/75%RH-
3M ND ND ND ND 0.01 0.01
50°C/90%RH-
1M ND ND ND ND 0.01 0.01
Talc - INITIAL ND ND ND 0.02 ND 0.02
40°C/75%RH-
1M ND ND ND ND ND 0
40°C/75%RH-
2M ND ND ND ND ND 0
40°C/75%RH-
3M ND ND ND ND ND 0
50°C/90%RH-
1M ND ND ND ND 0.01 0.01
Magnesium 
stearate 
-
INITIAL ND ND ND ND ND 0
40°C/75%RH-
1M ND ND ND ND ND 0
40°C/75%RH-
2M 0.01 ND ND ND 0.01 0.02
40°C/75%RH-
3M ND ND ND ND ND 0
50°C/90%RH-
1M ND ND ND ND 0.01 0.01
API+ HPMC K
4M + HPMC E
15 + 
Carbopol974p 
+ PVPk30 + 
Sodium bi 
carbonate + 
Lactose + Talc 
+ Magnesium 
stearate
1: 1: 
1:1:1:1
:1:1:1
INITIAL ND ND 0.01 0.03 ND 0.04
40°C/75%RH-
1M ND ND ND 0.02 0.01 0.03
40°C/75%RH-
2M ND ND 0.01 0.02 0.01 0.04
40°C/75%RH-
3M ND ND 0.01 0.03 ND 0.04
50°C/90%RH-
1M 0.01 ND ND 0.02 ND 0.03
 HPMC K 4M 
+ HPMC E 15 
+ 
Carbopol974p 
+ PVPk30 + 
Sodium bi 
carbonate + 
Lactose + Talc 
+ Magnesium 
stearate
1: 1: 
1:1:1:1
:1
INITIAL ND ND 0.01 0.03 ND 0.04
40°C/75%RH-
1M ND ND ND 0.02 0.01 0.03
40°C/75%RH-
2M ND ND 0.01 0.02 0.01 0.04
40°C/75%RH-
3M ND ND 0.01 0.03 ND 0.04
50°C/90%RH-
1M 0.01 ND ND 0.02 ND 0.03
ND- Not detected
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LIMIT: As per ICH Guideline Q3B (R2) impurities in new drug products, the 
limit for highest unknown impurity is NMT 0.2%
Conclusion:
Based on the above data it was concluded that, all the excipients which were taken 
for Drug: Excipients compatibility study were compatible with the drug substance. 
Based on the study results and innovator product composition the inactive 
excipients were selected for formulation of the product. 
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Figure 1 Sodiumbi Carbonate
Figure 1(a) Sodiumbi Carbonate
Figure 2 HPMCE15
Figure 2(a) HPMCE15
Figure 3 Levetiracetam
Figure 3(a) Levetiracetam
Figure 4 HPMCK4M
Figure 4(a) HPMCK4M
Figure 5 Carbopol 974P
Figure 6 Levetiracetam + HPMCK4M + HPMCE15 + Carbopol 974P +
Sodium bi carbonate
Figure 7 Levetiracetam + HPMCK4M + HPMCE15 + Carbopol 974P +
Sodium bi carbonate + Talc + Magnesium Stearate
Figure 7(a) Figure 7 Levetiracetam + HPMCK4M + HPMCE15 + Carbopol
974P + Sodium bi carbonate + Talc + Magnesium Stearate
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